<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>059 Pharmacology Ini-Cet 2024 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">24</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x3c9c61=_0x47ec;(function(_0x199e3e,_0x3a0e5f){const _0x200f7c=_0x47ec,_0x549e92=_0x199e3e();while(!![]){try{const _0x108046=parseInt(_0x200f7c(0x1ff))/0x1*(-parseInt(_0x200f7c(0x365))/0x2)+-parseInt(_0x200f7c(0x3b8))/0x3+parseInt(_0x200f7c(0x460))/0x4*(parseInt(_0x200f7c(0x24f))/0x5)+parseInt(_0x200f7c(0x3bf))/0x6*(parseInt(_0x200f7c(0x486))/0x7)+parseInt(_0x200f7c(0x41c))/0x8+parseInt(_0x200f7c(0x3f6))/0x9*(-parseInt(_0x200f7c(0x2d7))/0xa)+-parseInt(_0x200f7c(0x351))/0xb*(parseInt(_0x200f7c(0x3a5))/0xc);if(_0x108046===_0x3a0e5f)break;else _0x549e92['push'](_0x549e92['shift']());}catch(_0x5218fe){_0x549e92['push'](_0x549e92['shift']());}}}(_0x421b,0xa5581));const _0x209b81=(function(){const _0x5b5e35=_0x47ec,_0x407ff2={'zzSUp':function(_0x3c7ad8,_0xbeec83){return _0x3c7ad8<_0xbeec83;},'FCxbd':_0x5b5e35(0x423),'oGuoW':_0x5b5e35(0x37e),'eGVDc':_0x5b5e35(0x207),'xPZqM':function(_0x4338d8,_0x1bb07f){return _0x4338d8===_0x1bb07f;},'iFlzv':'tCaHa','paMpX':_0x5b5e35(0x405)};let _0x322995=!![];return function(_0x44a868,_0xc32689){const _0x10b2d4=_0x5b5e35;if(_0x407ff2[_0x10b2d4(0x3fc)](_0x407ff2['iFlzv'],_0x407ff2['paMpX'])){const _0x1bd565={'mptkd':function(_0x17311f,_0x3bc19e){const _0x1f2376=_0x10b2d4;return _0x407ff2[_0x1f2376(0x41a)](_0x17311f,_0x3bc19e);}},_0x3edb95=_0x4b46e5['parse'](_0x29def4[_0x10b2d4(0x39b)](_0x407ff2[_0x10b2d4(0x485)]))||[];_0x3edb95[_0x10b2d4(0x3b3)](_0x25f6d2=>{const _0x5a6439=_0x10b2d4;_0x25f6d2[_0x5a6439(0x4a1)][_0x5a6439(0x2c7)](_0x2f75ea[_0x5a6439(0x277)]()[_0x5a6439(0x357)](/ /g,'-'))&&(_0x1bd565[_0x5a6439(0x3f5)](_0x25f6d2[_0x5a6439(0x361)],_0x58c242[_0x5a6439(0x22f)])&&(_0x523f88[_0x25f6d2[_0x5a6439(0x361)]][_0x5a6439(0x3f9)]=!![]));});}else{const _0x243d24=_0x322995?function(){const _0x1c790c=_0x10b2d4;if(_0x407ff2[_0x1c790c(0x387)]===_0x407ff2[_0x1c790c(0x2a9)]){if(_0xefa2ae){const _0x270fea=_0x19f057['apply'](_0x5409d6,arguments);return _0x560c40=null,_0x270fea;}}else{if(_0xc32689){const _0x88ed01=_0xc32689[_0x1c790c(0x1ea)](_0x44a868,arguments);return _0xc32689=null,_0x88ed01;}}}:function(){};return _0x322995=![],_0x243d24;}};}()),_0x148489=_0x209b81(this,function(){const _0x53e9d4=_0x47ec,_0x2d312f={'SMJqe':_0x53e9d4(0x442)};return _0x148489[_0x53e9d4(0x39d)]()[_0x53e9d4(0x1f8)](_0x2d312f['SMJqe'])[_0x53e9d4(0x39d)]()['constructor'](_0x148489)[_0x53e9d4(0x1f8)](_0x2d312f[_0x53e9d4(0x457)]);});_0x148489();const _0x5b51cf=(function(){const _0x25cc91={'EfDRo':function(_0x4d8657,_0x137e27){return _0x4d8657===_0x137e27;},'mRrfe':'correct','lYIuM':function(_0x26a39f,_0x2661b0){return _0x26a39f!==_0x2661b0;}};let _0x5a7c7d=!![];return function(_0x14cbd,_0x2c2f4c){const _0x96ed2f=_0x47ec,_0x12af82={'yGkzY':function(_0x2fa68e,_0x30a265){const _0x514b8b=_0x47ec;return _0x25cc91[_0x514b8b(0x402)](_0x2fa68e,_0x30a265);},'HqPZL':function(_0x396d17,_0x2e130a){const _0x5b2c39=_0x47ec;return _0x25cc91[_0x5b2c39(0x402)](_0x396d17,_0x2e130a);},'oRwNd':'not_attempted','LLtWp':_0x25cc91[_0x96ed2f(0x3c3)],'NposK':function(_0xd0f9d3){return _0xd0f9d3();},'mBDfb':function(_0x57c80b,_0x1a9e66){const _0x1b2524=_0x96ed2f;return _0x25cc91[_0x1b2524(0x395)](_0x57c80b,_0x1a9e66);},'AMJMc':_0x96ed2f(0x22c),'qGFUX':function(_0x745200,_0x311887){return _0x745200!==_0x311887;},'KwuKu':_0x96ed2f(0x211)},_0x29dabd=_0x5a7c7d?function(){const _0x53f5a7=_0x96ed2f;if(_0x12af82[_0x53f5a7(0x212)](_0x12af82['AMJMc'],_0x53f5a7(0x3d3))){if(_0x2c2f4c){if(_0x12af82[_0x53f5a7(0x406)](_0x12af82['KwuKu'],_0x12af82['KwuKu'])){const _0x322616=_0x218953[_0x5c8343],_0x1300f2=_0x322616['correct_choice_id'];if(_0x12af82[_0x53f5a7(0x28f)](_0x3cc51f,null))return;const _0x4b60b6=_0x322616[_0x53f5a7(0x329)][_0xd649e1],_0xd4aac0=_0x12af82[_0x53f5a7(0x203)](_0x4b60b6['id'],_0x1300f2);if(_0x12af82[_0x53f5a7(0x203)](_0xefb72a[_0x39ea3a][_0x53f5a7(0x41d)],_0x12af82[_0x53f5a7(0x321)])){_0x5267ea[_0x53f5a7(0x40c)]++,_0x2d0b65[_0x53f5a7(0x478)]--;if(_0xd4aac0)_0x333645[_0x53f5a7(0x44b)]++;else _0x37cfaa[_0x53f5a7(0x46e)]++;}_0x184708[_0x280ac4][_0x53f5a7(0x41d)]=_0xd4aac0?_0x12af82[_0x53f5a7(0x470)]:_0x53f5a7(0x260),_0x32b9dc(),_0xf3d116(_0xd4aac0),_0x12af82[_0x53f5a7(0x37d)](_0x502670);}else{const _0x457271=_0x2c2f4c[_0x53f5a7(0x1ea)](_0x14cbd,arguments);return _0x2c2f4c=null,_0x457271;}}}else{const _0x5b729e=_0x44ff07?function(){if(_0x5c8a8e){const _0xd30e61=_0x178f3a['apply'](_0x1963f0,arguments);return _0x4e54d8=null,_0xd30e61;}}:function(){};return _0x57a3bf=![],_0x5b729e;}}:function(){};return _0x5a7c7d=![],_0x29dabd;};}()),_0x110796=_0x5b51cf(this,function(){const _0xf3cf6a=_0x47ec,_0xa679f8={'JRwtC':function(_0x30114d,_0x15b982){return _0x30114d<_0x15b982;},'rjvAP':function(_0x2919e2,_0x5bb15d){return _0x2919e2(_0x5bb15d);},'gHxqd':function(_0x4c6271,_0x559e8a){return _0x4c6271+_0x559e8a;},'mPtws':_0xf3cf6a(0x318),'kaege':_0xf3cf6a(0x398),'JQXTI':function(_0x57ff32){return _0x57ff32();},'PGcOs':function(_0x513fe9,_0x543c92){return _0x513fe9+_0x543c92;},'HbobP':function(_0x2b8c0c){return _0x2b8c0c();},'HFUoF':function(_0x49d9f6,_0x1416df){return _0x49d9f6!==_0x1416df;},'ElCTw':_0xf3cf6a(0x3c2),'kvCoW':'log','HSXKR':'warn','eNRBq':_0xf3cf6a(0x268),'uoIyU':_0xf3cf6a(0x42f),'EwssR':_0xf3cf6a(0x3e0),'PtuQs':_0xf3cf6a(0x305),'qhfpE':'trace','Hvchj':function(_0x3c1c9f,_0x586485){return _0x3c1c9f<_0x586485;},'KnVJP':'ZWoBv'};let _0x4730fe;try{const _0x45ac76=_0xa679f8['rjvAP'](Function,_0xa679f8[_0xf3cf6a(0x288)](_0xa679f8['gHxqd'](_0xa679f8['mPtws'],_0xa679f8['kaege']),');'));_0x4730fe=_0xa679f8['HbobP'](_0x45ac76);}catch(_0x3136e2){_0xa679f8[_0xf3cf6a(0x419)](_0xa679f8[_0xf3cf6a(0x1ed)],_0xf3cf6a(0x3c2))?_0x2905af['quizFile'][_0xf3cf6a(0x2c7)](_0x29b56a['toLowerCase']()[_0xf3cf6a(0x357)](/ /g,'-'))&&(_0xa679f8['JRwtC'](_0x376f5e[_0xf3cf6a(0x361)],_0x2d1eea[_0xf3cf6a(0x22f)])&&(_0x34d2b9[_0x3275ad[_0xf3cf6a(0x361)]]['bookmarked']=!![])):_0x4730fe=window;}const _0x1ff4ac=_0x4730fe['console']=_0x4730fe[_0xf3cf6a(0x218)]||{},_0x5196bd=[_0xa679f8[_0xf3cf6a(0x43f)],_0xa679f8[_0xf3cf6a(0x2fc)],_0xa679f8[_0xf3cf6a(0x33d)],_0xa679f8[_0xf3cf6a(0x284)],_0xa679f8['EwssR'],_0xa679f8[_0xf3cf6a(0x449)],_0xa679f8[_0xf3cf6a(0x3bc)]];for(let _0xf3efeb=0x0;_0xa679f8[_0xf3cf6a(0x3a2)](_0xf3efeb,_0x5196bd[_0xf3cf6a(0x22f)]);_0xf3efeb++){if(_0xa679f8[_0xf3cf6a(0x419)](_0xa679f8[_0xf3cf6a(0x4ad)],_0xf3cf6a(0x3d6))){const _0x15b9a3=_0x5b51cf['constructor'][_0xf3cf6a(0x4a0)][_0xf3cf6a(0x3e8)](_0x5b51cf),_0x2287f1=_0x5196bd[_0xf3efeb],_0x32ae7c=_0x1ff4ac[_0x2287f1]||_0x15b9a3;_0x15b9a3[_0xf3cf6a(0x414)]=_0x5b51cf[_0xf3cf6a(0x3e8)](_0x5b51cf),_0x15b9a3[_0xf3cf6a(0x39d)]=_0x32ae7c[_0xf3cf6a(0x39d)][_0xf3cf6a(0x3e8)](_0x32ae7c),_0x1ff4ac[_0x2287f1]=_0x15b9a3;}else{const _0x1dc3b6=_0xa679f8['rjvAP'](_0x1b2209,_0xa679f8[_0xf3cf6a(0x370)](_0xa679f8[_0xf3cf6a(0x370)](_0xa679f8[_0xf3cf6a(0x213)],_0xa679f8[_0xf3cf6a(0x314)]),');'));_0x4038d7=_0xa679f8[_0xf3cf6a(0x356)](_0x1dc3b6);}}});_0x110796();let questionsData=[{'text':_0x3c9c61(0x49d),'choices':[{'id':0x1,'text':'Dapagliflozin'},{'id':0x2,'text':'Sitagliptin'},{'id':0x3,'text':_0x3c9c61(0x3d4)},{'id':0x4,'text':'Glimeperide'}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x3f2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x326),'choices':[{'id':0x1,'text':'Oflaxacin'},{'id':0x2,'text':_0x3c9c61(0x26a)},{'id':0x3,'text':'Clofazamine'},{'id':0x4,'text':'Rifampicin'}],'correct_choice_id':0x3,'solution':_0x3c9c61(0x446),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x376),'choices':[{'id':0x1,'text':_0x3c9c61(0x44d)},{'id':0x2,'text':'Subtrochanteric\x20fractures'},{'id':0x3,'text':_0x3c9c61(0x21b)},{'id':0x4,'text':_0x3c9c61(0x37a)}],'correct_choice_id':0x4,'solution':_0x3c9c61(0x475),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20monoclonal\x20antibodies\x20is\x20not\x20a\x20HER\x20-\x201\x20inhibitor?','choices':[{'id':0x1,'text':_0x3c9c61(0x366)},{'id':0x2,'text':_0x3c9c61(0x2c9)},{'id':0x3,'text':'Panitumumab'},{'id':0x4,'text':_0x3c9c61(0x2fb)}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x383),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20G2P1\x20delivered\x20a\x20preterm\x20baby\x20at\x2036\x20weeks.\x20The\x20baby\x20was\x20admitted\x20in\x20the\x20NICU\x20for\x20a\x20week\x20and\x20was\x20given\x20expressed\x20breast\x20milk.\x20Unfortunately\x20the\x20baby\x20did\x20not\x20survive.\x20Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20to\x20reduce\x20the\x20engorgement\x20and\x20pain\x20of\x20the\x20lactating\x20breasts?','choices':[{'id':0x1,'text':'Cabergoline'},{'id':0x2,'text':'Sumatriptan'},{'id':0x3,'text':_0x3c9c61(0x214)},{'id':0x4,'text':_0x3c9c61(0x360)}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x3ba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x34c),'choices':[{'id':0x1,'text':_0x3c9c61(0x2d3)},{'id':0x2,'text':_0x3c9c61(0x2bd)},{'id':0x3,'text':_0x3c9c61(0x3ee)},{'id':0x4,'text':'Dabigatran'}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x32a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x338),'choices':[{'id':0x1,'text':_0x3c9c61(0x2d0)},{'id':0x2,'text':_0x3c9c61(0x27c)},{'id':0x3,'text':_0x3c9c61(0x2dc)},{'id':0x4,'text':_0x3c9c61(0x2fa)}],'correct_choice_id':0x2,'solution':_0x3c9c61(0x44e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20causes\x20a\x20decrease\x20in\x20serum\x20parathyroid\x20hormone?','choices':[{'id':0x1,'text':_0x3c9c61(0x40e)},{'id':0x2,'text':'Risedronate'},{'id':0x3,'text':'Furosemide'},{'id':0x4,'text':_0x3c9c61(0x285)}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x279),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x3d1),'choices':[{'id':0x1,'text':_0x3c9c61(0x228)},{'id':0x2,'text':'3,4'},{'id':0x3,'text':_0x3c9c61(0x236)},{'id':0x4,'text':_0x3c9c61(0x1f4)}],'correct_choice_id':0x2,'solution':'<p><strong>Ritonavir</strong>\x20and\x20<strong>benzbromarone</strong>\x20are\x20both\x20<strong>suicide\x20inhibitors.</strong>\u00a0</p>\x0a<p><strong>Suicide\x20inhibition</strong>\x20is\x20when\x20an\x20<strong>inhibitor</strong>\x20binds\x20to\x20an\x20<strong>enzyme</strong>\x20and\x20then\x20<strong>undergoes</strong>\x20a\x20reaction\x20to\x20form\x20an\x20<strong>irreversible\x20complex</strong>\x20with\x20the\x20<strong>enzyme,</strong>\x20inactivating\x20it\x20permanently.\x20Ritonavir\x20is\x20a\x20protease\x20inhibitor\x20used\x20in\x20HIV\x20treatment\x20and\x20benzbromarone\x20is\x20a\x20uricosuric\x20agent\x20used\x20to\x20treat\x20gout\x20by\x20increasing\x20uric\x20acid\x20excretion.\x20It\x20also\x20inhibits\x20CYP2C9\x20via\x20mechanism-based\x20(suicide)\x20inhibition.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Ethinyl\x20<strong>estradiol</strong>\x20is\x20a\x20synthetic\x20estrogen\x20used\x20in\x20oral\x20contraceptives\x20and\x20hormone\x20replacement\x20therapy.\x20It\x20acts\x20through\x20<strong>receptor-mediated</strong>\x20mechanisms,\x20not\x20through\x20suicide\x20inhibition.</p>\x0a<p><strong>Spironolactone</strong>\x20is\x20a\x20potassium-sparing\x20diuretic\x20and\x20aldosterone\x20antagonist.\x20It\x20works\x20by\x20competitively\x20<strong>inhibiting\x20aldosterone\x20receptors</strong>\x20in\x20the\x20distal\x20tubules\x20of\x20the\x20kidney,\x20not\x20through\x20suicide\x20inhibition.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x4aa),'choices':[{'id':0x1,'text':_0x3c9c61(0x232)},{'id':0x2,'text':_0x3c9c61(0x339)},{'id':0x3,'text':_0x3c9c61(0x237)},{'id':0x4,'text':_0x3c9c61(0x228)}],'correct_choice_id':0x2,'solution':_0x3c9c61(0x209),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x2c2),'choices':[{'id':0x1,'text':_0x3c9c61(0x263)},{'id':0x2,'text':_0x3c9c61(0x3db)},{'id':0x3,'text':_0x3c9c61(0x40f)},{'id':0x4,'text':_0x3c9c61(0x23c)}],'correct_choice_id':0x4,'solution':_0x3c9c61(0x32b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Inhaled\x20nitric\x20oxide\x20(iNO)\x20is\x20used\x20for?','choices':[{'id':0x1,'text':_0x3c9c61(0x243)},{'id':0x2,'text':_0x3c9c61(0x309)},{'id':0x3,'text':_0x3c9c61(0x246)},{'id':0x4,'text':'Erectile\x20dysfunction'}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x1f3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x333),'choices':[{'id':0x1,'text':_0x3c9c61(0x29b)},{'id':0x2,'text':_0x3c9c61(0x451)},{'id':0x3,'text':_0x3c9c61(0x29d)},{'id':0x4,'text':_0x3c9c61(0x302)}],'correct_choice_id':0x4,'solution':'<p><strong>Bromhexine</strong>\x20should\x20be\x20prescribed\x20for\x20a\x20patient\x20with\x20a\x20<strong>productive\x20cough</strong>,\x20as\x20it\x20<strong>liquifies</strong>\x20the\x20sputum.</p>\x0a<p>Bromhexine\x20belongs\x20to\x20a\x20class\x20of\x20drugs\x20called\x20<strong>mucolytics</strong>,\x20capable\x20of\x20inducing\x20thin\x20copious\x20bronchial\x20secretion.\x20It\x20<strong>depolymerizes</strong>\x20mucopolysaccharides\x20directly\x20as\x20well\x20as\x20by\x20liberating\x20lysosomal\x20enzymes-\x20the\x20network\x20of\x20fibers\x20in\x20tenacious\x20sputum\x20is\x20broken.\x20It\x20is\x20particularly\x20useful\x20if\x20mucus\x20plugs\x20are\x20present.</p>\x0a<p>Other\x20examples\x20of\x20mucolytics\x20are\x20ambroxol,\x20carbocisteine,\x20and\x20N-acetyl\x20cysteine.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p><strong>Codeine</strong>\x20and\x20<strong>dextromethorphan</strong>\x20belong\x20to\x20the\x20class\x20of\x20drugs\x20called\x20<strong>antitussives</strong>.\x20These\x20are\x20drugs\x20that\x20act\x20in\x20the\x20CNS\x20to\x20raise\x20the\x20threshold\x20of\x20the\x20cough\x20center\x20or\x20act\x20peripherally\x20in\x20the\x20respiratory\x20tract\x20to\x20reduce\x20tussal\x20impulses,\x20or\x20both\x20these\x20actions.\x20Because\x20they\x20aim\x20to\x20control\x20rather\x20than\x20eliminate\x20cough,\x20antitussive\x20drugs\x20should\x20be\x20used\x20only\x20for\x20<strong>dry\x20nonproductive</strong>\x20cough\x20or\x20if\x20it\x20is\x20unduly\x20tiring,\x20disturbs\x20sleep,\x20or\x20is\x20hazardous\x20(hernia,\x20piles,\x20cardiac\x20disease,\x20ocular\x20surgery).\u00a0</p>\x0a<p>Cough\x20is\x20a\x20defensive\x20reflex\x20and\x20its\x20suppression\x20may\x20be\x20inappropriate\x20in\x20bacterial\x20lung\x20infection.\x20Hence,\x20before\x20treatment\x20with\x20antitussives,\x20it\x20is\x20important\x20to\x20identify\x20underlying\x20causal\x20mechanisms\x20that\x20may\x20require\x20therapy.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x47f),'choices':[{'id':0x1,'text':_0x3c9c61(0x45c)},{'id':0x2,'text':'Metformin'},{'id':0x3,'text':_0x3c9c61(0x2ab)},{'id':0x4,'text':_0x3c9c61(0x3d4)}],'correct_choice_id':0x2,'solution':_0x3c9c61(0x2ed),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x2f3),'choices':[{'id':0x1,'text':'4h'},{'id':0x2,'text':_0x3c9c61(0x21c)},{'id':0x3,'text':_0x3c9c61(0x437)},{'id':0x4,'text':_0x3c9c61(0x42a)}],'correct_choice_id':0x3,'solution':_0x3c9c61(0x20c),'explanation_video':'','question_images':[],'explanation_images':[_0x3c9c61(0x41b)]},{'text':_0x3c9c61(0x267),'choices':[{'id':0x1,'text':_0x3c9c61(0x458)},{'id':0x2,'text':'High\x20dose\x20causes\x20cardiotoxicity\x20in\x20old\x20and\x20nephrotoxicity\x20in\x20young\x20patients'},{'id':0x3,'text':_0x3c9c61(0x374)},{'id':0x4,'text':_0x3c9c61(0x3be)}],'correct_choice_id':0x1,'solution':'<p>Acute\x20oral\x20overdose\x20results\x20primarily\x20in\x20<strong>cerebellar</strong>\x20and\x20<strong>vestibular</strong>\x20symptoms\x20and\x20high\x20doses\x20have\x20been\x20associated\x20with\x20marked\x20<strong>cerebellar\x20atrophy.</strong></p>\x0a<p>Dose-related\x20toxicity\x20of\x20phenytoin\x20causes\x20ataxia,\x20vertigo,\x20diplopia,\x20and\x20nystagmus.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20High\x20dose\x20causes\x20<strong>cardiotoxicity</strong>\x20in\x20both\x20old\x20and\x20young,\x20healthy\x20patients.\x20However,\x20cardiotoxicity\x20is\x20more\x20pronounced\x20and\x20frequent\x20in\x20older\x20patients\x20and\x20those\x20with\x20known\x20cardiac\x20diseases.</p>\x0a<p>Option\x20C:\x20These\x20complications\x20can\x20be\x20minimised\x20by\x20administering\x20<strong>fosphenytoin</strong>\x20at\x20a\x20rate\x20of\x20<strong>less\x20than\x20150\x20mg</strong>\x20of\x20phenytoin\x20sodium\x20equivalents\x20per\x20minute,\x20not\x20250\x20mg.</p>\x0a<p>Option\x20D:\x20Phenytoin\x20is\x20not\x20effective\x20in\x20generalised\x20absent\x20seizures.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'True\x20statement\x20about\x20Iron\x20Isomaltoside\x201000\x20is','choices':[{'id':0x1,'text':_0x3c9c61(0x378)},{'id':0x2,'text':_0x3c9c61(0x264)},{'id':0x3,'text':_0x3c9c61(0x487)},{'id':0x4,'text':_0x3c9c61(0x499)}],'correct_choice_id':0x1,'solution':'<p><strong>Iron\x20requirement</strong>\x20can\x20be\x20fulfilled\x20in\x20a\x20<strong>single\x20dose</strong>\x20is\x20true\x20regarding\x20<strong>Isomaltoside\x201000</strong>.</p>\x0a<p>Iron\x20isomaltose\x201000\x20is\x20a\x20new\x20IV\x20iron\x20formulation\x20that\x20can\x20supply\x20a\x20complete\x20replacement\x20dose\x20in\x20a\x20short,\x20single\x20visit.\x20It\x20is\x20used\x20in\x20adult\x20patients\x20with\x20an\x20intolerance\x20to\x20oral\x20iron\x20or\x20for\x20patients\x20with\x20CKD\x20not\x20requiring\x20hemodialysis.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20\u00a0Isomaltoside\x201000\x20is\x20not\x20more\x20immunogenic\x20than\x20<strong>iron\x20dextran</strong>.</p>\x0a<p>Option\x20\u00a0C:\x20The\x20strength\x20of\x20iron\x20binding\x20causes\x20a\x20controlled\x20slow\x20release\x20of\x20bioavailable\x20iron,\x20decreasing\x20the\x20risk\x20of\x20toxicity\x20from\x20labile-free\x20iron.\x20Its\x20decreased\x20<strong>toxicity</strong>\x20cannot\x20be\x20attributed\x20to\x20deposition\x20in\x20adipose\x20tissue.</p>\x0a<p>Option\x20D:\x20Isomaltoside\x201000\x20can\x20be\x20given\x20with\x20<strong>erythropoietin</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x22b),'choices':[{'id':0x1,'text':_0x3c9c61(0x2b8)},{'id':0x2,'text':'Ibalizumab'},{'id':0x3,'text':'Elvitregravir'},{'id':0x4,'text':_0x3c9c61(0x3b9)}],'correct_choice_id':0x2,'solution':'<p>The\x20drug\x20that\x20binds\x20to\x20CD4\x20and\x20has\x20an\x20action\x20on\x20both\x20CCR5\x20and\x20CXCR4\x20in\x20tropic\x20HIV\x20infections\x20is<strong>\x20Ibalizumab.</strong></p>\x0a<p><strong>Ibalizumab</strong>\x20is\x20an\x20anti-CD4\x20monoclonal\x20antibody\x20approved\x20for\x20use\x20in\x20the\x20treatment\x20of\x20<strong>multidrug-resistant\x20HIV-1</strong>.\x20It\x20has\x20action\x20on\x20both\x20<strong>CCR5\x20and\x20CXCR4</strong>\x20in\x20tropic\x20HIV\x20infections\x20and\x20is\x20administered\x20intravenously.\u00a0</p>\x0a<p>It\x20acts\x20as\x20an\x20entry\x20inhibitor.\x20It\x20blocks\x20HIV-1\x20from\x20infecting\x20CD4+\x20T\x20cells\x20by\x20binding\x20to\x20domain\x202\x20of\x20CD4\x20cells.\x20It\x20also\x20interferes\x20with\x20post-attachment\x20steps\x20required\x20for\x20the\x20entry\x20of\x20HIV-1\x20virus\x20particles\x20into\x20host\x20cells\x20and\x20thus\x20prevents\x20the\x20viral\x20transmission\x20that\x20occurs\x20via\x20cell-cell\x20fusion.\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Maraviroc</strong>\x20binds\x20to\x20the\x20host\x20cell\x20CCR5\x20receptor\x20to\x20block\x20the\x20binding\x20of\x20viral\x20gp120.\x20It\x20prevents\x20the\x20entry\x20of\x20the\x20viral\x20particles.\x20It\x20does\x20not\x20bind\x20to\x20CD4.</p>\x0a<p>Option\x20C:\x20<strong>Elvitegravir</strong>\x20is\x20an\x20integrase\x20inhibitor\x20that\x20inhibits\x20HIV\x201\x20viral\x20integrase\x20enzyme\x20and\x20prevents\x20proviral\x20DNA\x20integration\x20into\x20host\x20cells.</p>\x0a<p>Option\x20D:\x20<strong>Fosamprenavir</strong>\x20is\x20a\x20protease\x20inhibitor\x20that\x20blocks\x20the\x20viral\x20protease\x20enzyme\x20necessary\x20to\x20produce\x20mature\x20virions\x20upon\x20budding\x20from\x20the\x20host\x20membrane.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Inhibitors\x20of\x20Poly\x20ADP\x20ribose\x20polymerase\x20(PARP)\x20are\x20approved\x20for\x20BRCA-positive\x20breast\x20cancers.\x20Which\x20among\x20the\x20following\x20drugs\x20is\x20used?','choices':[{'id':0x1,'text':_0x3c9c61(0x30c)},{'id':0x2,'text':'Rucaparib'},{'id':0x3,'text':'Regorafenib'},{'id':0x4,'text':_0x3c9c61(0x416)}],'correct_choice_id':0x2,'solution':_0x3c9c61(0x2c0),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x38f),'choices':[{'id':0x1,'text':_0x3c9c61(0x2d4)},{'id':0x2,'text':_0x3c9c61(0x287)},{'id':0x3,'text':_0x3c9c61(0x2dd)},{'id':0x4,'text':_0x3c9c61(0x40b)}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x27f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x2e8),'choices':[{'id':0x1,'text':_0x3c9c61(0x3e5)},{'id':0x2,'text':'Contraindicated\x20in\x20patients\x20on\x20enzyme\x20inducer\x20drugs'},{'id':0x3,'text':'Acts\x20by\x20reactive\x20oxygen\x20species'},{'id':0x4,'text':_0x3c9c61(0x206)}],'correct_choice_id':0x2,'solution':'<p>Contraindicated\x20in\x20patients\x20on\x20enzyme\x20inducer\x20drugs\x20is\x20the\x20true\x20statement\x20regarding\x20<strong>Pretomanid</strong>.</p>\x0a<p><strong>Pretomanid</strong>\x20is\x20metabolized\x20in\x20part\x20by\x20CYP3A.\x20So\x20co-administration\x20with\x20strong\x20or\x20moderate\x20CYP3A\x20inducers\x20should\x20be\x20avoided.\x20Hence,\x20it\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20on\x20<strong>enzyme-inducer</strong>\x20drugs.</p>\x0a<p>Pretomanid\x20is\x20a\x20bicyclic\x20<strong>nitroimidazole</strong>\u00a0that\x20acts\x20by\x20inhibiting\x20mycolic\x20acid\x20(a\x20component\x20of\x20the\x20mycobacterial\x20cell\x20wall)\x20and\x20protein\x20synthesis\x20in\x20the\x20mycobacteria.</p>\x0a<p>Pretomanid\x20in\x20combination\x20with\x20Bedaquiline\x20and\x20Linezolid,\x20was\x20approved\x20by\x20the\x20FDA\x20in\x202019\x20for\x20the\x20treatment\x20of\x20adult\x20patients\x20with\x20<strong>Pre\x20(XDR)\x20TB\x20</strong>(resistant\x20to\x20rifampicin\x20and\x20any\x20fluoroquinolones)\x20and\x20for\x20patients\x20who\x20are\x20treatment-intolerant\x20or\x20nonresponsive\x20to\x20multidrug-resistant\x20pulmonary\x20<strong>(MDR)\x20TB\x20</strong>treatment.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20Pretomanid\x20is\x20given\x20for\x20<strong>Pre\x20-XDR\x20TB\x20(not\x20XDR\x20TB)\x20</strong>in\x20combination\x20with\x20Bedaquiline\x20and\x20Linezolid\x20(<strong>BPaL\x20regimen</strong>).\x20Pre-XDR\x20TB\x20is\x20resistant\x20to\x20rifampicin\x20and\x20any\x20fluoroquinolone,\x20and\x20therefore,\x20BPaL\x20is\x20given\x20to\x20such\x20patients.\u00a0</p>\x0a<p>Option\x20C:\x20Pretomanid\x20acts\x20by\x20<strong>reactive\x20nitrogen\x20species</strong>\x20like\x20NO\x20and\x20not\x20by\x20reactive\x20oxygen\x20species.</p>\x0a<p>Option\x20D:\x20Pretomanid\x20is\x20not\x20used\x20for\x20resistant\x20cases\x20of\x20malaria.</p>\x0a<p>*Note:\x20For\x20people\x20with\x20MDR/RR-TB,\x20the\x20regimen\x20comprises\x20<strong>bedaquiline\x20(B),\x20pretomanid\x20(Pa),\x20linezolid\x20(L)\x20and\x20moxifloxacin\x20(M)</strong>,\x20and\x20is\x20referred\x20to\x20as\x20<strong>BPaLM.</strong>\x20For\x20people\x20who\x20have\x20pre-XDR-TB,\x20the\x20regimen\x20can\x20be\x20used\x20without\x20moxifloxacin\x20(BPaL).</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x37b),'choices':[{'id':0x1,'text':'Phenytoin'},{'id':0x2,'text':_0x3c9c61(0x234)},{'id':0x3,'text':_0x3c9c61(0x438)},{'id':0x4,'text':_0x3c9c61(0x489)}],'correct_choice_id':0x3,'solution':_0x3c9c61(0x3ce),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3c9c61(0x386),'choices':[{'id':0x1,'text':_0x3c9c61(0x498)},{'id':0x2,'text':_0x3c9c61(0x26c)},{'id':0x3,'text':_0x3c9c61(0x3a4)},{'id':0x4,'text':_0x3c9c61(0x397)}],'correct_choice_id':0x1,'solution':_0x3c9c61(0x3cf),'explanation_video':'','question_images':[_0x3c9c61(0x2b6)],'explanation_images':[_0x3c9c61(0x453)]},{'text':'Match\x20the\x20treatment\x20with\x20its\x20respective\x20condition.','choices':[{'id':0x1,'text':_0x3c9c61(0x316)},{'id':0x2,'text':_0x3c9c61(0x1fb)},{'id':0x3,'text':_0x3c9c61(0x304)},{'id':0x4,'text':_0x3c9c61(0x3c8)}],'correct_choice_id':0x2,'solution':_0x3c9c61(0x368),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x3c9c61(0x359),hierarchy=[_0x3c9c61(0x2bb),_0x3c9c61(0x20f),_0x3c9c61(0x3df)];if(window['location'][_0x3c9c61(0x280)]['endsWith']('custom_quiz.html')){const customData=JSON[_0x3c9c61(0x3ef)](localStorage[_0x3c9c61(0x39b)](_0x3c9c61(0x24a)));if(customData){const TwbQOC=_0x3c9c61(0x1ee)[_0x3c9c61(0x3fa)]('|');let gQByVw=0x0;while(!![]){switch(TwbQOC[gQByVw++]){case'0':quizName=customData['name'];continue;case'1':hierarchy=customData[_0x3c9c61(0x445)];continue;case'2':document[_0x3c9c61(0x3e4)]('totalQuestions')['textContent']=questionsData[_0x3c9c61(0x22f)];continue;case'3':questionsData=customData[_0x3c9c61(0x3d9)];continue;case'4':document[_0x3c9c61(0x3e4)]('quizHierarchy')[_0x3c9c61(0x411)]=hierarchy['join'](_0x3c9c61(0x215));continue;case'5':document[_0x3c9c61(0x2b4)]=quizName+_0x3c9c61(0x46f);continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x3c9c61(0x4a5),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date[_0x3c9c61(0x43b)](),isQuizCompleted=![],questionStates=new Array(questionsData['length'])[_0x3c9c61(0x250)](null)[_0x3c9c61(0x27b)](()=>({'status':_0x3c9c61(0x415),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x3c9c61(0x22f)]};const urlParams=new URLSearchParams(window[_0x3c9c61(0x407)]['search']);currentQuestionIndex=Math[_0x3c9c61(0x35c)](parseInt(urlParams[_0x3c9c61(0x394)](_0x3c9c61(0x294)))||0x0,questionsData['length']-0x1);function goBack(){const _0x2c9616=_0x3c9c61,_0x285630={'cVkVE':function(_0x2d78f4,_0x362d36){return _0x2d78f4(_0x362d36);}};(isQuizCompleted||_0x285630[_0x2c9616(0x42e)](confirm,'Are\x20you\x20sure\x20you\x20want\x20to\x20leave\x20the\x20quiz?\x20Your\x20progress\x20will\x20be\x20lost.'))&&window['history']['back']();}function selectMode(_0xda20e2){const _0x47a80a=_0x3c9c61,_0x1d262d={'bvhxv':function(_0x4eadf8){return _0x4eadf8();}};currentMode=_0xda20e2,document[_0x47a80a(0x3e4)](_0x47a80a(0x431))[_0x47a80a(0x344)][_0x47a80a(0x40d)]='none',_0x1d262d['bvhxv'](initializeQuiz);}function initializeQuiz(){const _0x55d3a6=_0x3c9c61,_0x7bc92={'piObh':function(_0x3b5a77,_0x722950){return _0x3b5a77===_0x722950;},'uGThR':_0x55d3a6(0x2ac),'IEwWw':_0x55d3a6(0x3d0),'ExEQy':_0x55d3a6(0x34f),'xxDKJ':_0x55d3a6(0x40c),'UVWOK':function(_0x1a17d8,_0x1b5565){return _0x1a17d8>_0x1b5565;},'vjeGM':function(_0x3d51b1,_0x1aea42){return _0x3d51b1*_0x1aea42;},'RpRar':function(_0xba0029,_0x1247c3){return _0xba0029/_0x1247c3;},'bCNgz':'accuracy','gzfvA':function(_0x335b0f,_0x2e953b){return _0x335b0f+_0x2e953b;},'TDSoT':function(_0xb883fe,_0x282a7a){return _0xb883fe/_0x282a7a;},'MPEyu':function(_0x5a1881,_0x47888f){return _0x5a1881%_0x47888f;},'HgJMk':_0x55d3a6(0x295),'Qtlwh':_0x55d3a6(0x45a),'lSnWV':'markReviewBtn','Gmqru':'testModeReviewLegend','JKxLd':_0x55d3a6(0x306),'JdLZl':_0x55d3a6(0x274),'vtyzH':_0x55d3a6(0x380),'modTe':_0x55d3a6(0x2e9),'MgnHq':_0x55d3a6(0x343),'HFneU':'studyModeLegend','DoYVx':_0x55d3a6(0x2a5),'ygXBp':_0x55d3a6(0x303),'EZnJf':'flex','MyzIH':function(_0x38660c,_0x4fdd4e){return _0x38660c===_0x4fdd4e;},'IHbtj':function(_0xb8d819,_0x2043e0){return _0xb8d819!==_0x2043e0;},'wxniU':'JrHym','UjDtz':'timerContainer','KRLlr':function(_0x11942f){return _0x11942f();},'BpURx':function(_0x116ff1){return _0x116ff1();}};quizStartTime=Date[_0x55d3a6(0x43b)]();const _0x1789c8=document[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x23d)]),_0x517bf7=document[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x48f)]),_0x63fab6=document[_0x55d3a6(0x3e4)](_0x7bc92['Gmqru']),_0x32edcb=currentMode===_0x7bc92[_0x55d3a6(0x3b5)]||_0x7bc92['piObh'](currentMode,_0x7bc92[_0x55d3a6(0x331)]);document['getElementById'](_0x7bc92['vtyzH'])[_0x55d3a6(0x344)][_0x55d3a6(0x40d)]=_0x32edcb?_0x7bc92[_0x55d3a6(0x363)]:_0x7bc92[_0x55d3a6(0x320)],document[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x480)])['style']['display']=_0x32edcb?_0x7bc92[_0x55d3a6(0x363)]:_0x7bc92[_0x55d3a6(0x320)],document['getElementById'](_0x7bc92[_0x55d3a6(0x332)])[_0x55d3a6(0x344)][_0x55d3a6(0x40d)]=_0x32edcb?_0x55d3a6(0x343):'none',document[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x2d2)])[_0x55d3a6(0x344)][_0x55d3a6(0x40d)]=_0x32edcb?_0x7bc92[_0x55d3a6(0x320)]:_0x55d3a6(0x2e9),_0x1789c8['style'][_0x55d3a6(0x40d)]=_0x32edcb?_0x7bc92[_0x55d3a6(0x363)]:_0x55d3a6(0x448),_0x517bf7[_0x55d3a6(0x344)][_0x55d3a6(0x40d)]=_0x32edcb?_0x7bc92[_0x55d3a6(0x1f9)]:_0x7bc92[_0x55d3a6(0x363)],_0x63fab6['style']['display']=_0x32edcb?_0x7bc92['EZnJf']:_0x7bc92[_0x55d3a6(0x363)];if(_0x7bc92[_0x55d3a6(0x1e9)](currentMode,_0x7bc92['uGThR'])||_0x7bc92['MyzIH'](currentMode,_0x55d3a6(0x274))){if(_0x7bc92[_0x55d3a6(0x31f)](_0x7bc92[_0x55d3a6(0x47b)],_0x55d3a6(0x3b6)))document[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x474)])[_0x55d3a6(0x3c9)][_0x55d3a6(0x456)](_0x55d3a6(0x3f1));else{if(_0x5d30b7===_0x55d3a6(0x4a5)||_0x7bc92['piObh'](_0x5ed57b,_0x7bc92[_0x55d3a6(0x439)])){_0x384fb6[_0x55d3a6(0x3e4)](_0x7bc92['IEwWw'])[_0x55d3a6(0x411)]=_0x1711ad[_0x55d3a6(0x44b)],_0x17783d[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x44c)])[_0x55d3a6(0x411)]=_0x1bd8b5['incorrectAnswers'],_0x14d56a[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x3c4)])[_0x55d3a6(0x411)]=_0x44d02b[_0x55d3a6(0x40c)];const _0x1421d7=_0x7bc92[_0x55d3a6(0x26d)](_0x344439[_0x55d3a6(0x40c)],0x0)?_0x340773['round'](_0x7bc92[_0x55d3a6(0x1e6)](_0x7bc92[_0x55d3a6(0x21f)](_0x26b0b1[_0x55d3a6(0x44b)],_0x533110[_0x55d3a6(0x40c)]),0x64)):0x0;_0x15c416['getElementById'](_0x7bc92[_0x55d3a6(0x2e5)])[_0x55d3a6(0x411)]=_0x7bc92[_0x55d3a6(0x310)](_0x1421d7,'%'),_0xde35da[_0x55d3a6(0x296)]=_0x53a17b[_0x55d3a6(0x2cc)]((_0x1ddf4b,_0x41859d)=>_0x1ddf4b+_0x41859d[_0x55d3a6(0x295)],0x0);const _0x6bc6cf=_0x47b0d1[_0x55d3a6(0x45e)](_0x7bc92[_0x55d3a6(0x3af)](_0x200a71[_0x55d3a6(0x296)],0x3e8)),_0xbf5ee6=_0x4224d1[_0x55d3a6(0x45e)](_0x7bc92['RpRar'](_0x6bc6cf,0x3c)),_0x24d6ce=_0x7bc92[_0x55d3a6(0x3dd)](_0x6bc6cf,0x3c);_0x2fdb75[_0x55d3a6(0x3e4)](_0x7bc92[_0x55d3a6(0x479)])['textContent']=_0x7bc92[_0x55d3a6(0x310)](_0x7bc92[_0x55d3a6(0x310)](_0xbf5ee6,':'),_0x24d6ce[_0x55d3a6(0x39d)]()[_0x55d3a6(0x3a7)](0x2,'0'));}}}_0x7bc92['KRLlr'](loadBookmarkedQuestions),_0x7bc92[_0x55d3a6(0x2bc)](generateQuestionNav),updateStats(),displayQuestion();}function generateQuestionNav(){const _0xb0c206=_0x3c9c61,_0x228fdc={'XsqnM':'questionNav','RtEoc':function(_0x5d8546,_0x5e7b94){return _0x5d8546<_0x5e7b94;},'JyEXr':_0xb0c206(0x488),'WdkXN':function(_0x33c217,_0x29cbb4){return _0x33c217+_0x29cbb4;}},_0xae5d1b=document[_0xb0c206(0x3e4)](_0x228fdc[_0xb0c206(0x465)]);_0xae5d1b[_0xb0c206(0x49f)]='';for(let _0x5697df=0x0;_0x228fdc[_0xb0c206(0x317)](_0x5697df,questionsData[_0xb0c206(0x22f)]);_0x5697df++){const _0x418a56=document['createElement'](_0x228fdc[_0xb0c206(0x428)]);_0x418a56[_0xb0c206(0x411)]=_0x228fdc['WdkXN'](_0x5697df,0x1),_0x418a56['className']=_0xb0c206(0x2d6),_0x418a56[_0xb0c206(0x25f)]=()=>jumpToQuestion(_0x5697df),_0x418a56['id']=_0xb0c206(0x364)+_0x5697df,_0xae5d1b[_0xb0c206(0x265)](_0x418a56);}updateQuestionNav();}function updateQuestionNav(){const _0x2c189b=_0x3c9c61,_0x151747={'ZpcKG':function(_0x52993a,_0x30bb65){return _0x52993a===_0x30bb65;},'hzsyp':_0x2c189b(0x4a3),'UhRcj':_0x2c189b(0x260),'PRmmf':_0x2c189b(0x22a),'BszMO':function(_0x20407c,_0x2dac2b){return _0x20407c<_0x2dac2b;},'vKxqZ':function(_0xe1a7c5,_0x2fc117){return _0xe1a7c5!==_0x2fc117;},'MNMdB':_0x2c189b(0x403),'bmTBM':_0x2c189b(0x2b0),'AzCgA':_0x2c189b(0x2cf),'IpRhW':_0x2c189b(0x4ac),'gKpAf':'nav-btn-bookmarked','Qqqxp':_0x2c189b(0x3c1),'DzQbp':'study','OAQoG':function(_0x62bb04,_0x25583a){return _0x62bb04===_0x25583a;},'grKqj':_0x2c189b(0x275),'FJuDL':function(_0x1a918c,_0xad2807){return _0x1a918c===_0xad2807;},'CKoFP':'nav-btn-incorrect','rejRF':function(_0x4c67c1,_0x1794b4){return _0x4c67c1!==_0x1794b4;},'AbZet':'nav-btn-answered','YCrWa':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20'};for(let _0xb65baa=0x0;_0x151747[_0x2c189b(0x3e7)](_0xb65baa,questionsData['length']);_0xb65baa++){if(_0x151747[_0x2c189b(0x30f)](_0x151747['MNMdB'],_0x151747['bmTBM'])){const _0x1b3dca=document[_0x2c189b(0x3e4)](_0x2c189b(0x364)+_0xb65baa),_0xb39c11=questionStates[_0xb65baa];let _0x38af55='';if(_0x151747[_0x2c189b(0x23e)](_0xb65baa,currentQuestionIndex))_0x151747[_0x2c189b(0x30f)](_0x151747['AzCgA'],_0x151747[_0x2c189b(0x455)])?_0x3f0432['history'][_0x2c189b(0x2ec)]():_0x38af55=_0x151747['IpRhW'];else{if(_0xb39c11['bookmarked'])_0x38af55=_0x151747[_0x2c189b(0x2d9)];else{if(_0xb39c11['markedForReview'])_0x38af55=_0x151747[_0x2c189b(0x1e5)];else{if(currentMode===_0x151747['DzQbp']||_0x151747['ZpcKG'](currentMode,'timed_study')){if(_0x151747[_0x2c189b(0x44f)](_0xb39c11[_0x2c189b(0x41d)],_0x151747[_0x2c189b(0x2ba)]))_0x38af55=_0x151747[_0x2c189b(0x3de)];else{if(_0x151747[_0x2c189b(0x25e)](_0xb39c11['status'],_0x151747[_0x2c189b(0x48a)]))_0x38af55=_0x151747[_0x2c189b(0x1f2)];else _0x38af55='nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20';}}else{if(_0x151747[_0x2c189b(0x1ef)](_0xb39c11[_0x2c189b(0x30b)],null))_0x38af55=_0x151747[_0x2c189b(0x37f)];else _0x38af55=_0x151747[_0x2c189b(0x33e)];}}}}_0x1b3dca[_0x2c189b(0x400)]=_0x2c189b(0x2c3)+_0x38af55;}else{const _0x1dd14a=_0x3d97a9['choices'][_0x260535[_0x2c189b(0x30b)]];_0x151747['ZpcKG'](_0x1dd14a['id'],_0x377b9c)?(_0x160cc0=_0x151747[_0x2c189b(0x2ba)],_0x94213e=_0x2c189b(0x2a3)):(_0x57173d=_0x151747[_0x2c189b(0x48a)],_0x4878f9=_0x151747[_0x2c189b(0x2f0)]);}}}function jumpToQuestion(_0x37213c){const _0x4dc880=_0x3c9c61,_0x254b38={'tSvzB':function(_0x350163,_0x53e3e8){return _0x350163>=_0x53e3e8;},'vFaIY':function(_0x123326,_0x487472){return _0x123326<_0x487472;},'ovIgc':function(_0x2690ea,_0x532939){return _0x2690ea-_0x532939;},'vlARj':function(_0x4fd112){return _0x4fd112();}};_0x254b38[_0x4dc880(0x3c5)](_0x37213c,0x0)&&_0x254b38[_0x4dc880(0x463)](_0x37213c,questionsData[_0x4dc880(0x22f)])&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x4dc880(0x295)]+=_0x254b38[_0x4dc880(0x384)](Date[_0x4dc880(0x43b)](),questionStartTime)),currentQuestionIndex=_0x37213c,_0x254b38[_0x4dc880(0x281)](displayQuestion));}function updateStats(){const _0x20f46a=_0x3c9c61,_0x42614e={'gWsOv':function(_0x2154e9,_0x39652a){return _0x2154e9===_0x39652a;},'JaUiR':_0x20f46a(0x4a5),'LwMKF':function(_0x4c93ee,_0xe01fca){return _0x4c93ee===_0xe01fca;},'scuOt':'timed_study','DChcF':'correctCount','xytka':_0x20f46a(0x34f),'tLjmI':'totalAttempted','rQDdn':function(_0x375b45,_0xde6201){return _0x375b45*_0xde6201;},'lciQV':function(_0x1a4f7d,_0x39a0d4){return _0x1a4f7d/_0x39a0d4;},'QvQSE':'accuracy','SWTDY':function(_0x2323ee,_0x35beea){return _0x2323ee+_0x35beea;},'sponM':function(_0x1ae763,_0x5af580){return _0x1ae763%_0x5af580;},'jtvWL':'timeSpent','sQcgd':function(_0x3df137,_0x1cff09){return _0x3df137+_0x1cff09;}};if(_0x42614e[_0x20f46a(0x41e)](currentMode,_0x42614e[_0x20f46a(0x49a)])||_0x42614e[_0x20f46a(0x430)](currentMode,_0x42614e[_0x20f46a(0x46c)])){document['getElementById'](_0x42614e[_0x20f46a(0x464)])['textContent']=stats['correctAnswers'],document[_0x20f46a(0x3e4)](_0x42614e[_0x20f46a(0x426)])[_0x20f46a(0x411)]=stats[_0x20f46a(0x46e)],document['getElementById'](_0x42614e[_0x20f46a(0x3eb)])[_0x20f46a(0x411)]=stats[_0x20f46a(0x40c)];const _0x507ff4=stats[_0x20f46a(0x40c)]>0x0?Math[_0x20f46a(0x2b1)](_0x42614e['rQDdn'](_0x42614e[_0x20f46a(0x230)](stats[_0x20f46a(0x44b)],stats[_0x20f46a(0x40c)]),0x64)):0x0;document[_0x20f46a(0x3e4)](_0x42614e[_0x20f46a(0x217)])[_0x20f46a(0x411)]=_0x42614e[_0x20f46a(0x2eb)](_0x507ff4,'%'),stats['totalTime']=questionStates[_0x20f46a(0x2cc)]((_0x511b78,_0x1bb636)=>_0x511b78+_0x1bb636[_0x20f46a(0x295)],0x0);const _0x6d5b97=Math['floor'](stats['totalTime']/0x3e8),_0x5ba0c8=Math[_0x20f46a(0x45e)](_0x42614e[_0x20f46a(0x230)](_0x6d5b97,0x3c)),_0x807cab=_0x42614e[_0x20f46a(0x239)](_0x6d5b97,0x3c);document['getElementById'](_0x42614e['jtvWL'])[_0x20f46a(0x411)]=_0x42614e[_0x20f46a(0x35d)](_0x42614e[_0x20f46a(0x2eb)](_0x5ba0c8,':'),_0x807cab[_0x20f46a(0x39d)]()[_0x20f46a(0x3a7)](0x2,'0'));}}function setupVideo(_0x5ddc59,_0x230b39){const _0x42d130=_0x3c9c61,_0xcfa2e0={'UFUmf':_0x42d130(0x47c)};if(Hls[_0x42d130(0x262)]()){const _0x54dbc8=new Hls();_0x54dbc8[_0x42d130(0x20b)](_0x230b39),_0x54dbc8['attachMedia'](_0x5ddc59);}else _0x5ddc59['canPlayType'](_0xcfa2e0[_0x42d130(0x3d8)])&&(_0x5ddc59['src']=_0x230b39);}function displayQuestion(){const _0x79d7cf=_0x3c9c61,_0x2bb238={'hWxpq':_0x79d7cf(0x3c1),'erSDa':function(_0x2e267f,_0x48782d){return _0x2e267f(_0x48782d);},'FEWBn':function(_0x2fbed6,_0x2c99c4){return _0x2fbed6+_0x2c99c4;},'glnqU':function(_0x2514e6,_0x177e93){return _0x2514e6+_0x177e93;},'QAnde':_0x79d7cf(0x398),'SaVKP':function(_0x15b2ad){return _0x15b2ad();},'evXWV':_0x79d7cf(0x311),'JEosk':_0x79d7cf(0x42f),'PMzEA':_0x79d7cf(0x3e0),'ctZBc':_0x79d7cf(0x305),'ALuKi':_0x79d7cf(0x3a3),'xFPMe':function(_0x44d709,_0x307e81){return _0x44d709<_0x307e81;},'vYljw':function(_0x1b0392,_0x42a4c6){return _0x1b0392===_0x42a4c6;},'yKlXQ':_0x79d7cf(0x2ce),'vbcBo':'modeModal','mgBFV':_0x79d7cf(0x448),'OzouQ':function(_0xad12e9,_0x2ad4c3){return _0xad12e9===_0x2ad4c3;},'ZZaRi':_0x79d7cf(0x3b7),'ZgyBh':_0x79d7cf(0x283),'pcvcD':_0x79d7cf(0x440),'vZeWh':function(_0x3e7013,_0x1de180){return _0x3e7013(_0x1de180);},'iGTUi':'data-option-index','HcPon':_0x79d7cf(0x417),'VlZOn':_0x79d7cf(0x2e2),'IMBCl':_0x79d7cf(0x4a8),'WhddZ':function(_0x1f1847,_0x2125a2){return _0x1f1847*_0x2125a2;},'keMro':function(_0x3d7c65,_0x3ee51c){return _0x3d7c65/_0x3ee51c;},'VhEuv':'progressBar','CwEtd':'currentQuestion','iClxb':function(_0x59cc6f,_0x456709){return _0x59cc6f+_0x456709;},'dDeKP':'prevBtn','qFlHw':'solutionContainer','AahjM':_0x79d7cf(0x3f1),'PexVA':_0x79d7cf(0x2f1),'fTfMg':_0x79d7cf(0x290),'RkqQF':'questionMedia','FSEEW':_0x79d7cf(0x301),'gRzOu':_0x79d7cf(0x401),'xTXOO':function(_0x41adb4){return _0x41adb4();},'BVHQP':function(_0x46c80e){return _0x46c80e();},'qvggc':function(_0x3ee0ae,_0x1ea1f7){return _0x3ee0ae===_0x1ea1f7;},'vQWbU':_0x79d7cf(0x274)};if(!questionsData||questionsData[_0x79d7cf(0x22f)]===0x0){if(_0x2bb238[_0x79d7cf(0x22d)]!==_0x2bb238[_0x79d7cf(0x22d)])_0x89e2e0=_0x2bb238[_0x79d7cf(0x481)];else{document[_0x79d7cf(0x3e4)](_0x2bb238[_0x79d7cf(0x422)])[_0x79d7cf(0x49f)]=_0x2bb238[_0x79d7cf(0x49c)];return;}};const _0x3f42a5=questionsData[currentQuestionIndex];questionStartTime=Date[_0x79d7cf(0x43b)](),selectedOption=questionStates[currentQuestionIndex][_0x79d7cf(0x30b)];const _0x4446cd=_0x2bb238[_0x79d7cf(0x202)](_0x2bb238[_0x79d7cf(0x432)](_0x2bb238[_0x79d7cf(0x26f)](currentQuestionIndex,0x1),questionsData[_0x79d7cf(0x22f)]),0x64);document[_0x79d7cf(0x3e4)](_0x2bb238['VhEuv'])[_0x79d7cf(0x344)][_0x79d7cf(0x3ea)]=_0x2bb238[_0x79d7cf(0x272)](_0x4446cd,'%'),document[_0x79d7cf(0x3e4)](_0x2bb238[_0x79d7cf(0x31e)])[_0x79d7cf(0x411)]=_0x2bb238[_0x79d7cf(0x2f6)](currentQuestionIndex,0x1),updateQuestionNav(),document[_0x79d7cf(0x3e4)](_0x2bb238[_0x79d7cf(0x291)])['disabled']=_0x2bb238[_0x79d7cf(0x252)](currentQuestionIndex,0x0),document['getElementById'](_0x2bb238[_0x79d7cf(0x2a1)])['classList'][_0x79d7cf(0x323)](_0x2bb238[_0x79d7cf(0x2bf)]),document[_0x79d7cf(0x3e4)](_0x2bb238[_0x79d7cf(0x422)])[_0x79d7cf(0x49f)]=_0x3f42a5[_0x79d7cf(0x372)]||_0x2bb238[_0x79d7cf(0x345)];let _0x56d844='';if(_0x3f42a5['question_audio'])_0x56d844+=_0x79d7cf(0x484)+_0x3f42a5['question_audio']+_0x79d7cf(0x39f);if(_0x3f42a5[_0x79d7cf(0x452)])_0x56d844+=_0x79d7cf(0x34e)+_0x3f42a5[_0x79d7cf(0x452)]+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';if(_0x3f42a5[_0x79d7cf(0x20e)]){if(_0x2bb238['fTfMg']===_0x79d7cf(0x409)){let _0x497566;try{const _0x3019c8=toYPBD[_0x79d7cf(0x2e3)](_0xb691ac,toYPBD[_0x79d7cf(0x272)](toYPBD[_0x79d7cf(0x26f)](_0x79d7cf(0x318),toYPBD[_0x79d7cf(0x2ef)]),');'));_0x497566=toYPBD[_0x79d7cf(0x389)](_0x3019c8);}catch(_0x532a24){_0x497566=_0xb4725f;}const _0x139e72=_0x497566[_0x79d7cf(0x218)]=_0x497566['console']||{},_0x7d8fc5=[_0x79d7cf(0x391),toYPBD[_0x79d7cf(0x2a4)],_0x79d7cf(0x268),toYPBD[_0x79d7cf(0x2be)],toYPBD[_0x79d7cf(0x308)],toYPBD['ctZBc'],toYPBD[_0x79d7cf(0x2a6)]];for(let _0xfbed58=0x0;toYPBD[_0x79d7cf(0x28d)](_0xfbed58,_0x7d8fc5[_0x79d7cf(0x22f)]);_0xfbed58++){const _0x4e57d1=_0x23995e['constructor']['prototype']['bind'](_0x5e80ff),_0x589eee=_0x7d8fc5[_0xfbed58],_0x488f5d=_0x139e72[_0x589eee]||_0x4e57d1;_0x4e57d1[_0x79d7cf(0x414)]=_0x202a32[_0x79d7cf(0x3e8)](_0x1dd3c3),_0x4e57d1['toString']=_0x488f5d['toString'][_0x79d7cf(0x3e8)](_0x488f5d),_0x139e72[_0x589eee]=_0x4e57d1;}}else _0x3f42a5[_0x79d7cf(0x20e)][_0x79d7cf(0x3b3)](_0x45e802=>{const _0x34d075=_0x79d7cf;if(_0x45e802)_0x56d844+=_0x34d075(0x4a7)+_0x45e802+_0x34d075(0x231);});}document[_0x79d7cf(0x3e4)](_0x2bb238[_0x79d7cf(0x24e)])[_0x79d7cf(0x49f)]=_0x56d844;const _0x4ab795=document[_0x79d7cf(0x3e4)](_0x2bb238['FSEEW']);_0x4ab795[_0x79d7cf(0x49f)]='',_0x4ab795[_0x79d7cf(0x3c9)]['remove'](_0x2bb238[_0x79d7cf(0x441)]),_0x3f42a5[_0x79d7cf(0x329)]&&Array[_0x79d7cf(0x39c)](_0x3f42a5[_0x79d7cf(0x329)])&&(_0x3f42a5['choices']['forEach']((_0x57c2f6,_0x90b3b9)=>{const _0x3cc298=_0x79d7cf,_0x372cfb=String[_0x3cc298(0x42d)](0x41+_0x90b3b9),_0x5d2073=_0x2bb238['vYljw'](selectedOption,_0x90b3b9),_0x1ac92f=document['createElement'](_0x2bb238[_0x3cc298(0x358)]);_0x1ac92f[_0x3cc298(0x49f)]=_0x3cc298(0x355)+(_0x5d2073?_0x3cc298(0x46d):'')+_0x3cc298(0x3e2)+_0x90b3b9+_0x3cc298(0x37c)+_0x372cfb+_0x3cc298(0x3ae)+(_0x57c2f6[_0x3cc298(0x372)]||_0x2bb238[_0x3cc298(0x272)](_0x3cc298(0x1fd),_0x2bb238['FEWBn'](_0x90b3b9,0x1)))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x4ab795[_0x3cc298(0x265)](_0x1ac92f);}),_0x4ab795[_0x79d7cf(0x435)](_0x79d7cf(0x200),function(_0x23d249){const _0x5e5604=_0x79d7cf;if(_0x2bb238['OzouQ'](_0x2bb238['ZZaRi'],_0x2bb238['ZgyBh']))_0xc25ea1['getElementById'](_0x2bb238[_0x5e5604(0x352)])[_0x5e5604(0x344)][_0x5e5604(0x40d)]=_0x2bb238[_0x5e5604(0x2a0)];else{const _0x374e89=_0x23d249[_0x5e5604(0x433)]['closest'](_0x2bb238[_0x5e5604(0x278)]);if(_0x374e89){const _0x62c624=_0x2bb238[_0x5e5604(0x4a6)](parseInt,_0x374e89[_0x5e5604(0x1f1)](_0x2bb238[_0x5e5604(0x2a7)]));selectOption(_0x62c624);}}})),_0x2bb238['xTXOO'](updateBookmarkButton),_0x2bb238[_0x79d7cf(0x249)](updateMarkReviewButton),(currentMode===_0x79d7cf(0x2ac)||_0x2bb238[_0x79d7cf(0x4a9)](currentMode,_0x2bb238[_0x79d7cf(0x49e)]))&&!isQuizCompleted&&_0x2bb238[_0x79d7cf(0x39a)](startTimer);}function selectOption(_0x1cc2c1){const _0x25712b=_0x3c9c61,_0x3f726d={'hIBII':'selected','yrOmO':_0x25712b(0x45a),'oTauT':'markReviewBtn','UfCdt':function(_0x14bc99,_0x590aa1){return _0x14bc99===_0x590aa1;},'gzsvd':'test','TlAEO':'none','EgpMg':_0x25712b(0x343),'vjoAN':_0x25712b(0x2a5),'BYQLA':_0x25712b(0x303),'LMMBF':_0x25712b(0x448),'HsaUd':_0x25712b(0x2ac),'SpLYf':function(_0x16f621,_0x47d1a5){return _0x16f621===_0x47d1a5;},'dxyOm':_0x25712b(0x274),'XorwY':'timerContainer','cunCt':_0x25712b(0x3f1),'zgDth':function(_0x46a74c){return _0x46a74c();},'Ypqyh':_0x25712b(0x301),'PmQaR':_0x25712b(0x401),'bTNlL':function(_0x213feb,_0x52d625){return _0x213feb-_0x52d625;},'hktnk':function(_0x5d5999,_0x144fc2){return _0x5d5999===_0x144fc2;},'fMnLc':'study','oxMis':function(_0x424c27,_0x4e2ba1,_0x3c97c5){return _0x424c27(_0x4e2ba1,_0x3c97c5);},'tAKeC':function(_0x567446,_0x358f9d){return _0x567446!==_0x358f9d;},'eCSIr':'BGfqO','lEBrf':'iZJMw','hGBcJ':function(_0x401bcf,_0x58f2f3){return _0x401bcf===_0x58f2f3;},'XfXkU':_0x25712b(0x415),'IXdWi':function(_0x56b91c){return _0x56b91c();}},_0x6e0ae2=document['getElementById'](_0x3f726d[_0x25712b(0x43a)]);if(_0x6e0ae2['classList']['contains'](_0x3f726d['PmQaR']))return;questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x3f726d[_0x25712b(0x38c)](Date[_0x25712b(0x43b)](),questionStartTime),questionStartTime=Date[_0x25712b(0x43b)]());selectedOption=_0x1cc2c1,questionStates[currentQuestionIndex][_0x25712b(0x30b)]=_0x1cc2c1,document[_0x25712b(0x32e)](_0x25712b(0x440))[_0x25712b(0x3b3)]((_0x15772d,_0x4afffe)=>{const _0x3fad29=_0x25712b;_0x15772d[_0x3fad29(0x3c9)][_0x3fad29(0x3c0)](_0x3f726d[_0x3fad29(0x41f)],_0x4afffe===_0x1cc2c1);});if(_0x3f726d['hktnk'](currentMode,_0x3f726d[_0x25712b(0x2c5)])||_0x3f726d['UfCdt'](currentMode,'timed_study'))_0x3f726d['oxMis'](setTimeout,processAnswer,0x12c);else{if(_0x3f726d[_0x25712b(0x497)](_0x3f726d[_0x25712b(0x3a8)],_0x3f726d[_0x25712b(0x2c1)]))_0x3f726d[_0x25712b(0x25a)](questionStates[currentQuestionIndex][_0x25712b(0x41d)],_0x3f726d[_0x25712b(0x2cb)])&&(questionStates[currentQuestionIndex][_0x25712b(0x41d)]='answered',stats[_0x25712b(0x40c)]++,stats[_0x25712b(0x478)]--),_0x3f726d[_0x25712b(0x2e4)](updateQuestionNav);else{_0x183ceb=_0x18a60e[_0x25712b(0x43b)]();const _0x12e930=_0x3f6223[_0x25712b(0x3e4)](_0x3f726d[_0x25712b(0x224)]),_0x120685=_0x34d1d0[_0x25712b(0x3e4)](_0x3f726d[_0x25712b(0x466)]),_0x109e16=_0x48aad9[_0x25712b(0x3e4)]('testModeReviewLegend'),_0x30cb79=_0x3f726d[_0x25712b(0x2db)](_0x3e5f9d,_0x3f726d[_0x25712b(0x30e)])||_0x3f726d['UfCdt'](_0x312bdf,_0x25712b(0x274));_0x50fc31[_0x25712b(0x3e4)](_0x25712b(0x380))[_0x25712b(0x344)]['display']=_0x30cb79?_0x3f726d['TlAEO']:_0x3f726d['EgpMg'],_0x1660ff[_0x25712b(0x3e4)](_0x25712b(0x23a))[_0x25712b(0x344)][_0x25712b(0x40d)]=_0x30cb79?_0x3f726d[_0x25712b(0x462)]:_0x3f726d['EgpMg'],_0x5d0925[_0x25712b(0x3e4)](_0x3f726d[_0x25712b(0x2f8)])['style'][_0x25712b(0x40d)]=_0x30cb79?_0x25712b(0x343):_0x3f726d[_0x25712b(0x462)],_0xb7e353[_0x25712b(0x3e4)](_0x3f726d[_0x25712b(0x388)])[_0x25712b(0x344)][_0x25712b(0x40d)]=_0x30cb79?_0x3f726d['EgpMg']:_0x3f726d[_0x25712b(0x462)],_0x12e930[_0x25712b(0x344)][_0x25712b(0x40d)]=_0x30cb79?_0x25712b(0x2e9):_0x3f726d[_0x25712b(0x25d)],_0x120685[_0x25712b(0x344)][_0x25712b(0x40d)]=_0x30cb79?_0x3f726d[_0x25712b(0x25d)]:'none',_0x109e16[_0x25712b(0x344)][_0x25712b(0x40d)]=_0x30cb79?_0x3f726d[_0x25712b(0x25d)]:_0x3f726d['TlAEO'],(_0x59c867===_0x3f726d[_0x25712b(0x3ab)]||_0x3f726d['SpLYf'](_0x46dbdb,_0x3f726d[_0x25712b(0x2b2)]))&&_0xee4c0b['getElementById'](_0x3f726d[_0x25712b(0x3a9)])[_0x25712b(0x3c9)][_0x25712b(0x456)](_0x3f726d[_0x25712b(0x382)]),_0x3f726d['zgDth'](_0x36df9b),_0x3f726d[_0x25712b(0x255)](_0x8fb622),_0x1cf36a(),_0x3f726d[_0x25712b(0x255)](_0x3d8b64);}}}function processAnswer(){const _0x5a53b6=_0x3c9c61,_0x3be5b0={'IOoRg':function(_0xf0f94b,_0x3154ef){return _0xf0f94b===_0x3154ef;},'UfEyT':_0x5a53b6(0x415),'sMyrl':_0x5a53b6(0x2c8),'kZwqC':'correct','VrLha':function(_0x19f43b){return _0x19f43b();},'uOqIk':function(_0x4997c9,_0x3cc052){return _0x4997c9(_0x3cc052);}},_0x4c01f3=questionsData[currentQuestionIndex],_0x267b26=_0x4c01f3[_0x5a53b6(0x31a)];if(selectedOption===null)return;const _0x19ffb4=_0x4c01f3['choices'][selectedOption],_0x972e50=_0x19ffb4['id']===_0x267b26;if(_0x3be5b0[_0x5a53b6(0x3d5)](questionStates[currentQuestionIndex][_0x5a53b6(0x41d)],_0x3be5b0[_0x5a53b6(0x2ff)])){if(_0x3be5b0[_0x5a53b6(0x43d)]===_0x3be5b0[_0x5a53b6(0x43d)]){stats['totalAttempted']++,stats['notAttempted']--;if(_0x972e50)stats[_0x5a53b6(0x44b)]++;else stats[_0x5a53b6(0x46e)]++;}else _0x5a9ce7=_0x5a53b6(0x4ac);}questionStates[currentQuestionIndex][_0x5a53b6(0x41d)]=_0x972e50?_0x3be5b0[_0x5a53b6(0x315)]:_0x5a53b6(0x260),_0x3be5b0['VrLha'](updateStats),_0x3be5b0[_0x5a53b6(0x2ae)](showInlineFeedback,_0x972e50),_0x3be5b0[_0x5a53b6(0x42c)](updateQuestionNav);}function showInlineFeedback(_0x501f02){const _0x4c895b=_0x3c9c61,_0x3e89c2={'INCYw':'selected','lYbHA':_0x4c895b(0x4a3),'hVoQC':function(_0x249e97,_0x57f0ff){return _0x249e97===_0x57f0ff;},'yNEuA':_0x4c895b(0x260),'UNfDS':function(_0x1c3f8f,_0x19dd76){return _0x1c3f8f!==_0x19dd76;},'CrpfI':_0x4c895b(0x4a5),'QvkBL':function(_0x59cd1e,_0x41ce80){return _0x59cd1e!==_0x41ce80;},'mqtQz':_0x4c895b(0x2ac),'RVSmf':_0x4c895b(0x301),'CGefc':_0x4c895b(0x401),'dLZcD':function(_0x3372fb,_0x31f302,_0xef75fb){return _0x3372fb(_0x31f302,_0xef75fb);}};if(_0x3e89c2[_0x4c895b(0x3ad)](currentMode,_0x3e89c2[_0x4c895b(0x27d)])&&_0x3e89c2[_0x4c895b(0x424)](currentMode,_0x3e89c2[_0x4c895b(0x240)]))return;const _0x2cecf3=document[_0x4c895b(0x3e4)](_0x3e89c2[_0x4c895b(0x3ac)]),_0x11b382=_0x2cecf3[_0x4c895b(0x32e)](_0x4c895b(0x440)),_0x2c2bca=questionsData[currentQuestionIndex],_0x4fc1be=_0x2c2bca[_0x4c895b(0x31a)];let _0x21beb6=_0x2c2bca[_0x4c895b(0x329)][_0x4c895b(0x226)](_0x5cd031=>_0x5cd031['id']===_0x4fc1be);_0x2cecf3[_0x4c895b(0x3c9)][_0x4c895b(0x323)](_0x3e89c2[_0x4c895b(0x31d)]),_0x11b382[_0x4c895b(0x3b3)]((_0x5d4fbc,_0x3530c3)=>{const _0x3ef9a0=_0x4c895b;_0x5d4fbc[_0x3ef9a0(0x3c9)][_0x3ef9a0(0x456)](_0x3e89c2[_0x3ef9a0(0x29c)]);if(_0x3530c3===_0x21beb6)_0x5d4fbc[_0x3ef9a0(0x3c9)]['add'](_0x3e89c2[_0x3ef9a0(0x1fa)]);else{if(_0x3e89c2[_0x3ef9a0(0x425)](_0x3530c3,selectedOption)&&!_0x501f02)_0x5d4fbc['classList']['add'](_0x3e89c2['yNEuA']);}}),_0x3e89c2[_0x4c895b(0x3ca)](setTimeout,showSolution,0x5dc);}function showSolution(){const _0x74616f=_0x3c9c61,_0x2c1d88={'AyuiA':_0x74616f(0x448),'TneIZ':function(_0x1ded90){return _0x1ded90();},'uEaBc':function(_0x28033d,_0x2795b9){return _0x28033d!==_0x2795b9;},'wJLPa':_0x74616f(0x2ac),'bCHOF':_0x74616f(0x34d),'czmgv':'No\x20solution\x20provided','LqchK':_0x74616f(0x270),'Pvtfe':_0x74616f(0x3cc),'ZYPBF':_0x74616f(0x3f1),'jiTrX':function(_0xbd3d99,_0x5c3c1a,_0x302b22){return _0xbd3d99(_0x5c3c1a,_0x302b22);},'vqFMI':function(_0x1d241b,_0x415012){return _0x1d241b===_0x415012;},'hiblK':'HPrss','KUZpD':_0x74616f(0x30d),'fbGxt':_0x74616f(0x3cb),'antQj':_0x74616f(0x1fe),'zQkkQ':_0x74616f(0x269)};if(_0x2c1d88[_0x74616f(0x461)](currentMode,_0x74616f(0x4a5))&&currentMode!==_0x2c1d88['wJLPa'])return;const _0x4bc447=questionsData[currentQuestionIndex];document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x330)])[_0x74616f(0x49f)]=_0x4bc447['solution']||_0x2c1d88['czmgv'];const _0x44864f=document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x490)]),_0x1f071d=document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x353)]),_0x2f0692=_0x4bc447[_0x74616f(0x1ec)];if(_0x2f0692){_0x44864f[_0x74616f(0x3c9)][_0x74616f(0x456)](_0x2c1d88['ZYPBF']);if(_0x2f0692[_0x74616f(0x2c7)](_0x74616f(0x3b2)))_0x2c1d88[_0x74616f(0x2ee)](setupVideo,_0x1f071d,_0x2f0692);else _0x1f071d[_0x74616f(0x434)]=_0x2f0692;}else _0x2c1d88[_0x74616f(0x21d)](_0x2c1d88[_0x74616f(0x469)],_0x2c1d88[_0x74616f(0x2ad)])?!_0xf1b70d[_0x74616f(0x407)]['pathname'][_0x74616f(0x1f7)](_0x74616f(0x375))?_0x5d5d9f[_0x74616f(0x3e4)](_0x74616f(0x431))[_0x74616f(0x344)][_0x74616f(0x40d)]=_0x2c1d88[_0x74616f(0x210)]:_0x2c1d88[_0x74616f(0x293)](_0xe87a03):_0x44864f[_0x74616f(0x3c9)][_0x74616f(0x323)](_0x74616f(0x3f1));const _0x196675=document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x340)]);_0x196675[_0x74616f(0x49f)]='';_0x4bc447[_0x74616f(0x36c)]&&(_0x196675[_0x74616f(0x49f)]+=_0x74616f(0x27a)+_0x4bc447[_0x74616f(0x36c)]+_0x74616f(0x39f));_0x4bc447[_0x74616f(0x369)]&&(_0x196675['innerHTML']+=_0x74616f(0x3bb)+_0x4bc447[_0x74616f(0x369)]+_0x74616f(0x39f));const _0x149337=document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x454)]);_0x149337['innerHTML']='',_0x4bc447[_0x74616f(0x42b)]&&_0x4bc447[_0x74616f(0x42b)]['forEach'](_0x1aa71f=>{const _0xc49549=_0x74616f;if(_0x1aa71f)_0x149337[_0xc49549(0x49f)]+=_0xc49549(0x36f)+_0x1aa71f+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}),document[_0x74616f(0x3e4)](_0x2c1d88[_0x74616f(0x271)])[_0x74616f(0x3c9)][_0x74616f(0x456)](_0x2c1d88['ZYPBF']);}function submitQuiz(){const _0x4cde37=_0x3c9c61,_0x49c157={'dcugJ':_0x4cde37(0x45a),'JyKDf':'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','Zscok':_0x4cde37(0x242),'vVgyB':_0x4cde37(0x4a2),'dEoJb':_0x4cde37(0x33c),'gnOwB':function(_0x2f4357,_0x7ccbd){return _0x2f4357!==_0x7ccbd;},'zLxOt':function(_0x4cb2c6,_0x4063fa){return _0x4cb2c6===_0x4063fa;},'YdAnb':'correct','tUgJu':_0x4cde37(0x260),'CKzpo':function(_0x4df87a,_0x1893fe){return _0x4df87a===_0x1893fe;},'NBqSZ':function(_0x5408d1,_0x2169cb){return _0x5408d1!==_0x2169cb;},'pODML':'iBnGm','UHKFp':function(_0x274b5f,_0x2b9639){return _0x274b5f!==_0x2b9639;},'TlHAw':_0x4cde37(0x325),'GjGsq':function(_0xc9308e,_0x38f46d){return _0xc9308e(_0x38f46d);},'xxXJR':'Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','rBgCm':function(_0x355db9,_0x384e15){return _0x355db9-_0x384e15;},'zOBXA':_0x4cde37(0x216),'xkHPw':function(_0x4b34c4,_0x43e7f1){return _0x4b34c4+_0x43e7f1;},'cxuJp':function(_0x3eb8fc,_0x4dfd4a,_0x5e64aa,_0x3cc496,_0xe69ebb){return _0x3eb8fc(_0x4dfd4a,_0x5e64aa,_0x3cc496,_0xe69ebb);},'QpTBe':function(_0x4edebc,_0x50046f){return _0x4edebc-_0x50046f;}};if(timer)_0x49c157[_0x4cde37(0x413)](clearInterval,timer);if(!_0x49c157['GjGsq'](confirm,_0x49c157[_0x4cde37(0x3e1)]))return;isQuizCompleted=!![];let _0x45e458=0x0,_0x28b052=0x0;const _0x1633b1=_0x49c157['rBgCm'](Date[_0x4cde37(0x43b)](),quizStartTime);questionsData[_0x4cde37(0x3b3)]((_0x3ef20b,_0x567077)=>{const _0x3462f1=_0x4cde37;if(_0x49c157['CKzpo']('MqKKY',_0x3462f1(0x347))){const _0x556e7a=questionStates[_0x567077];if(_0x49c157['NBqSZ'](_0x556e7a[_0x3462f1(0x30b)],null)){if(_0x49c157[_0x3462f1(0x2df)](_0x3ef20b[_0x3462f1(0x329)][_0x556e7a[_0x3462f1(0x30b)]]['id'],_0x3ef20b['correct_choice_id'])){if(_0x49c157[_0x3462f1(0x3e6)](_0x3462f1(0x3b0),_0x49c157[_0x3462f1(0x1fc)]))_0x45e458++,_0x556e7a[_0x3462f1(0x41d)]=_0x49c157[_0x3462f1(0x223)];else{const _0x4c26a8=_0x4fb8ce[_0x3462f1(0x3e4)](_0x49c157['dcugJ']),_0x46c2d1=_0x50e230[_0x3462f1(0x3e4)](_0x3462f1(0x3fe)),_0x551b32=_0x27b655[_0x47d396][_0x3462f1(0x3f9)];_0x4c26a8[_0x3462f1(0x400)]=_0x551b32?_0x49c157[_0x3462f1(0x32f)]:_0x49c157['Zscok'],_0x46c2d1[_0x3462f1(0x411)]=_0x551b32?_0x49c157[_0x3462f1(0x468)]:_0x49c157[_0x3462f1(0x2da)];}}else _0x49c157['UHKFp'](_0x49c157[_0x3462f1(0x30a)],_0x49c157[_0x3462f1(0x30a)])?_0x2b6c52[_0x3462f1(0x434)]=_0x11b527:(_0x28b052++,_0x556e7a[_0x3462f1(0x41d)]=_0x49c157['tUgJu']);}}else{const _0x2c1220=_0xbb8b29[_0x4e7059];_0x49c157[_0x3462f1(0x3e6)](_0x2c1220[_0x3462f1(0x30b)],null)&&(_0x49c157['zLxOt'](_0x3171a1[_0x3462f1(0x329)][_0x2c1220[_0x3462f1(0x30b)]]['id'],_0x3c909f[_0x3462f1(0x31a)])?(_0x2adc28++,_0x2c1220[_0x3462f1(0x41d)]=_0x49c157[_0x3462f1(0x223)]):(_0x35b1e5++,_0x2c1220['status']=_0x49c157[_0x3462f1(0x3aa)]));}});const _0x6669b=JSON[_0x4cde37(0x3ef)](localStorage['getItem'](_0x49c157['zOBXA']))||[];_0x6669b[_0x4cde37(0x404)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x4cde37(0x43b)](),'totalTime':_0x1633b1,'stats':{'correct':_0x45e458,'incorrect':_0x28b052,'notAttempted':_0x49c157['rBgCm'](questionsData[_0x4cde37(0x22f)],_0x49c157[_0x4cde37(0x292)](_0x45e458,_0x28b052))}}),localStorage[_0x4cde37(0x1e4)](_0x49c157['zOBXA'],JSON['stringify'](_0x6669b)),_0x49c157['cxuJp'](showPerformanceAnalysis,_0x45e458,_0x28b052,_0x49c157[_0x4cde37(0x233)](questionsData[_0x4cde37(0x22f)],_0x45e458+_0x28b052),_0x1633b1);}function showPerformanceAnalysis(_0x5c3e00,_0x2e6c47,_0x3ea755,_0x2538e6){const _0x336e71=_0x3c9c61,_0x5e27d6={'iUkwl':_0x336e71(0x342),'lOTgf':function(_0x2b6d42,_0x434d55){return _0x2b6d42+_0x434d55;},'fSAUc':function(_0x54aab1,_0x2e5ea1){return _0x54aab1*_0x2e5ea1;},'lcHWV':function(_0x2101c0,_0x5307cf){return _0x2101c0/_0x5307cf;},'HgMwL':function(_0x3d40c2,_0x10423f){return _0x3d40c2+_0x10423f;},'EnRsL':function(_0x1cdabd,_0x7d6b78){return _0x1cdabd-_0x7d6b78;},'qzASF':function(_0x1a8a9d,_0x166882){return _0x1a8a9d/_0x166882;},'CSmFj':_0x336e71(0x1f6),'wtTYJ':_0x336e71(0x3c7),'otjyX':_0x336e71(0x2b5),'osgYD':_0x336e71(0x26b),'RAcwY':function(_0x23c37a,_0x590e87){return _0x23c37a/_0x590e87;},'UEnyf':function(_0xee46f,_0x1a2319){return _0xee46f/_0x1a2319;},'eiiTH':function(_0x4b8bce,_0x4d970c){return _0x4b8bce%_0x4d970c;},'IsLyF':_0x336e71(0x3f1)},_0x18f95f=document[_0x336e71(0x3e4)](_0x5e27d6[_0x336e71(0x377)]),_0x132b1c=_0x5e27d6[_0x336e71(0x3fd)](_0x5c3e00,_0x2e6c47)>0x0?Math[_0x336e71(0x2b1)](_0x5e27d6['fSAUc'](_0x5e27d6[_0x336e71(0x1f5)](_0x5c3e00,_0x5e27d6[_0x336e71(0x3fb)](_0x5c3e00,_0x2e6c47)),0x64)):0x0,_0x230d87=_0x5e27d6[_0x336e71(0x3ec)](_0x5e27d6[_0x336e71(0x3ec)](0x2,Math['PI']),0x41),_0x3a2a44=document['getElementById'](_0x336e71(0x299));_0x3a2a44[_0x336e71(0x344)][_0x336e71(0x259)]=_0x230d87+'\x20'+_0x230d87,_0x3a2a44[_0x336e71(0x344)]['strokeDashoffset']=_0x5e27d6[_0x336e71(0x24b)](_0x230d87,_0x5e27d6['qzASF'](_0x132b1c,0x64)*_0x230d87),document[_0x336e71(0x3e4)](_0x5e27d6[_0x336e71(0x3a6)])['textContent']=_0x132b1c+'%',document[_0x336e71(0x3e4)](_0x336e71(0x35e))[_0x336e71(0x411)]=questionsData[_0x336e71(0x22f)],document[_0x336e71(0x3e4)](_0x5e27d6['wtTYJ'])[_0x336e71(0x411)]=_0x5c3e00,document['getElementById'](_0x336e71(0x341))[_0x336e71(0x411)]=_0x2e6c47,document[_0x336e71(0x3e4)](_0x5e27d6[_0x336e71(0x23f)])[_0x336e71(0x411)]=_0x3ea755;const _0x48d050=Math[_0x336e71(0x45e)](_0x2538e6/0xea60),_0x308898=Math[_0x336e71(0x45e)](_0x5e27d6[_0x336e71(0x3bd)](_0x2538e6%0xea60,0x3e8));document[_0x336e71(0x3e4)](_0x5e27d6[_0x336e71(0x421)])['textContent']=_0x48d050+':'+_0x308898[_0x336e71(0x39d)]()[_0x336e71(0x3a7)](0x2,'0');const _0x25cde6=_0x5e27d6[_0x336e71(0x2de)](_0x2538e6,questionsData[_0x336e71(0x22f)]),_0x38d268=Math[_0x336e71(0x45e)](_0x5e27d6[_0x336e71(0x222)](_0x25cde6,0xea60)),_0x465b34=Math[_0x336e71(0x45e)](_0x5e27d6[_0x336e71(0x45d)](_0x25cde6,0xea60)/0x3e8);document['getElementById'](_0x336e71(0x2fe))[_0x336e71(0x411)]=_0x38d268+':'+_0x465b34[_0x336e71(0x39d)]()['padStart'](0x2,'0'),_0x18f95f[_0x336e71(0x3c9)][_0x336e71(0x456)](_0x5e27d6[_0x336e71(0x45b)]);}function closePerformanceModal(){const _0x3686f6=_0x3c9c61,_0x55c0e8={'SBAYo':_0x3686f6(0x342),'kNQlX':_0x3686f6(0x3f1)};document[_0x3686f6(0x3e4)](_0x55c0e8[_0x3686f6(0x3dc)])[_0x3686f6(0x3c9)][_0x3686f6(0x323)](_0x55c0e8['kNQlX']);}function reviewQuestions(){const _0x32ac11=_0x3c9c61,_0x3f4d53={'qyRzQ':'customQuizData','JYcrg':function(_0x1a3af5,_0x251742){return _0x1a3af5+_0x251742;},'GQZkM':function(_0x779f0e,_0x54d735){return _0x779f0e===_0x54d735;},'MykkU':_0x32ac11(0x2ce),'UXjee':'selected','xgJcW':function(_0x32df23,_0x34f188){return _0x32df23(_0x34f188);},'nBFVp':'click','wLBhJ':_0x32ac11(0x393),'pOyiu':_0x32ac11(0x307),'uzMXU':_0x32ac11(0x362),'ABNID':function(_0x5b0e1e,_0x3c1607){return _0x5b0e1e===_0x3c1607;},'ZJDyR':_0x32ac11(0x427),'GIfiX':_0x32ac11(0x36e),'YRNJQ':function(_0x21bc35,_0x365b09){return _0x21bc35!==_0x365b09;},'HsYio':function(_0x23e494,_0x49ef62){return _0x23e494!==_0x49ef62;},'lXEmf':_0x32ac11(0x491),'NnuXj':'TzSlM','pGQhJ':'Correct','PJJAU':_0x32ac11(0x22a),'ZRSzr':_0x32ac11(0x4a3),'DnVwF':function(_0x1165eb,_0xb4303d){return _0x1165eb===_0xb4303d;},'NXIMu':'gray','nMrQP':'No\x20solution\x20available.','mQfjo':function(_0x3a14e4){return _0x3a14e4();}};document[_0x32ac11(0x3e4)]('questionReviewSection')['classList'][_0x32ac11(0x456)](_0x32ac11(0x3f1));const _0x1dcb9f=document[_0x32ac11(0x3e4)](_0x32ac11(0x46b));_0x1dcb9f['innerHTML']='',questionsData[_0x32ac11(0x3b3)]((_0x4b6900,_0x29f8cf)=>{const _0x413789=_0x32ac11,_0x3a3234={'aqvlE':function(_0x1d4289,_0xce8410){const _0x5587a7=_0x47ec;return _0x3f4d53[_0x5587a7(0x2cd)](_0x1d4289,_0xce8410);},'XgujB':function(_0x2a1236,_0x433576){const _0x39658d=_0x47ec;return _0x3f4d53[_0x39658d(0x2a8)](_0x2a1236,_0x433576);},'esetr':_0x3f4d53['MykkU'],'izfLa':_0x3f4d53[_0x413789(0x29a)],'vLSby':function(_0x596b61,_0x33e60b){const _0x4adf3b=_0x413789;return _0x3f4d53[_0x4adf3b(0x24c)](_0x596b61,_0x33e60b);},'bKoLj':function(_0x5daf38,_0x3e494c){return _0x5daf38(_0x3e494c);},'BDTFF':_0x3f4d53[_0x413789(0x29f)],'pJMQN':function(_0x41ae71,_0x464606){return _0x41ae71-_0x464606;},'rOsWE':function(_0x1a8ed1,_0x320086){return _0x1a8ed1<_0x320086;},'cinmX':function(_0x35bc4e,_0x3bd5b7){return _0x35bc4e(_0x3bd5b7);},'yEzxb':_0x3f4d53['wLBhJ'],'XwsLt':_0x3f4d53[_0x413789(0x2ea)],'PwYJm':_0x3f4d53['uzMXU']};if(_0x3f4d53[_0x413789(0x229)](_0x3f4d53['ZJDyR'],_0x413789(0x2f5))){const _0x9f7e45={'cBFPi':function(_0x46022b,_0x1414c1){return _0x3a3234['aqvlE'](_0x46022b,_0x1414c1);},'ethUe':function(_0x469da5,_0x650d75){const _0x65775c=_0x413789;return _0x3a3234[_0x65775c(0x3ff)](_0x469da5,_0x650d75);},'mLhxG':_0x3a3234['esetr'],'RzPaA':_0x3a3234[_0x413789(0x40a)],'MYymW':'Option\x20','KiLHl':function(_0x1d370a,_0x530dbf){const _0x20901a=_0x413789;return _0x3a3234[_0x20901a(0x276)](_0x1d370a,_0x530dbf);},'mMUOd':_0x413789(0x3b4),'eNVEV':function(_0x17d615,_0x227781){const _0x2fb6be=_0x413789;return _0x3a3234[_0x2fb6be(0x23b)](_0x17d615,_0x227781);}};_0x5e04e8['choices'][_0x413789(0x3b3)]((_0x854d13,_0x5094be)=>{const _0x4dbd6a=_0x413789,_0x28ce42=_0x1dba6c[_0x4dbd6a(0x42d)](_0x9f7e45[_0x4dbd6a(0x48e)](0x41,_0x5094be)),_0x3d9c93=_0x9f7e45[_0x4dbd6a(0x28e)](_0x3dcd9b,_0x5094be),_0x479117=_0x3f60ac[_0x4dbd6a(0x379)](_0x9f7e45[_0x4dbd6a(0x336)]);_0x479117[_0x4dbd6a(0x49f)]=_0x4dbd6a(0x355)+(_0x3d9c93?_0x9f7e45[_0x4dbd6a(0x38b)]:'')+_0x4dbd6a(0x3e2)+_0x5094be+_0x4dbd6a(0x37c)+_0x28ce42+_0x4dbd6a(0x3ae)+(_0x854d13['text']||_0x9f7e45[_0x4dbd6a(0x48e)](_0x9f7e45[_0x4dbd6a(0x251)],_0x9f7e45[_0x4dbd6a(0x48e)](_0x5094be,0x1)))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x3f7b8d[_0x4dbd6a(0x265)](_0x479117);}),_0x17d485[_0x413789(0x435)](_0x3a3234[_0x413789(0x273)],function(_0x3db97a){const _0xef2c89=_0x413789,_0x564de9=_0x3db97a[_0xef2c89(0x433)][_0xef2c89(0x27e)](_0xef2c89(0x440));if(_0x564de9){const _0x24e2de=_0x9f7e45['KiLHl'](_0x45ecb4,_0x564de9[_0xef2c89(0x1f1)](_0x9f7e45[_0xef2c89(0x48b)]));_0x9f7e45[_0xef2c89(0x245)](_0x5baf65,_0x24e2de);}});}else{const _0x2ea227=questionStates[_0x29f8cf],_0x131727=_0x4b6900[_0x413789(0x31a)];let _0x10290f=_0x413789(0x2fd),_0x4b23e0=_0x3f4d53[_0x413789(0x348)];if(_0x3f4d53[_0x413789(0x3a1)](_0x2ea227[_0x413789(0x30b)],null)){if(_0x3f4d53[_0x413789(0x2d5)](_0x3f4d53[_0x413789(0x26e)],_0x3f4d53[_0x413789(0x33b)])){const _0x18c614=_0x4b6900[_0x413789(0x329)][_0x2ea227[_0x413789(0x30b)]];_0x3f4d53[_0x413789(0x2a8)](_0x18c614['id'],_0x131727)?(_0x10290f=_0x413789(0x4a3),_0x4b23e0=_0x3f4d53[_0x413789(0x3d7)]):(_0x10290f='incorrect',_0x4b23e0=_0x3f4d53[_0x413789(0x238)]);}else _0x2de4f3[_0x413789(0x35f)](_0x3f4d53['qyRzQ']);}const _0x3c15db=document[_0x413789(0x379)]('div');_0x3c15db[_0x413789(0x400)]=_0x413789(0x3f3)+_0x10290f;let _0x2a69db=(_0x4b6900[_0x413789(0x329)]||[])[_0x413789(0x27b)]((_0x182005,_0x282989)=>{const _0x21d2d4=_0x413789;if(_0x3a3234[_0x21d2d4(0x3ff)](_0x3a3234[_0x21d2d4(0x33a)],_0x3a3234[_0x21d2d4(0x35a)])){const _0x1d97c7=_0x3a3234[_0x21d2d4(0x48c)](_0xb8545d(_0x296df1[_0x21d2d4(0x28b)]),0x1),_0x629b67=_0x593712[_0x21d2d4(0x32e)](_0x21d2d4(0x440));if(_0x3a3234[_0x21d2d4(0x36b)](_0x1d97c7,_0x629b67['length']))_0x3a3234[_0x21d2d4(0x247)](_0x31cc85,_0x1d97c7);}else{const _0x117347=_0x3a3234['XgujB'](_0x2ea227['selectedAnswer'],_0x282989),_0x355060=_0x3a3234[_0x21d2d4(0x3ff)](_0x182005['id'],_0x131727);let _0x4de90d='border-gray-600';if(_0x355060)_0x4de90d=_0x3a3234[_0x21d2d4(0x227)];else{if(_0x117347)_0x4de90d=_0x21d2d4(0x289);}return _0x21d2d4(0x436)+_0x4de90d+_0x21d2d4(0x399)+String[_0x21d2d4(0x42d)](0x41+_0x282989)+'</span><span>'+_0x182005[_0x21d2d4(0x372)]+'</span></div>';}})[_0x413789(0x28a)]('');const _0x37d5d1=_0x4b6900[_0x413789(0x1ec)]?_0x413789(0x396)+_0x29f8cf+_0x413789(0x36a)+_0x4b6900['explanation_video']+_0x413789(0x258):'';let _0x451fb4='';if(_0x4b6900[_0x413789(0x36c)])_0x451fb4+=_0x413789(0x221)+_0x4b6900[_0x413789(0x36c)]+_0x413789(0x39f);if(_0x4b6900[_0x413789(0x369)])_0x451fb4+=_0x413789(0x43c)+_0x4b6900['explanation_audio_hin']+_0x413789(0x39f);let _0x5da6e5=(_0x4b6900[_0x413789(0x42b)]||[])['map'](_0x1d59c4=>_0x1d59c4?'<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x1d59c4+_0x413789(0x241):'')['join']('');_0x3c15db['innerHTML']='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20'+(_0x29f8cf+0x1)+_0x413789(0x473)+(_0x3f4d53['GQZkM'](_0x10290f,_0x3f4d53[_0x413789(0x371)])?_0x413789(0x3f7):_0x3f4d53[_0x413789(0x31c)](_0x10290f,_0x413789(0x260))?'red':_0x3f4d53[_0x413789(0x204)])+_0x413789(0x3f0)+_0x4b23e0+_0x413789(0x3da)+_0x4b6900[_0x413789(0x372)]+_0x413789(0x33f)+_0x2a69db+_0x413789(0x35b)+(_0x4b6900[_0x413789(0x412)]||_0x3f4d53['nMrQP'])+_0x413789(0x300)+_0x37d5d1+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x451fb4+_0x413789(0x483)+_0x5da6e5+_0x413789(0x205),_0x1dcb9f['appendChild'](_0x3c15db);}}),_0x3f4d53[_0x32ac11(0x2d8)](initializeReviewVideos);}function initializeReviewVideos(){const _0x87681a=_0x3c9c61,_0x2a09a1={'yQzoq':function(_0x17ec42,_0x110cb5){return _0x17ec42<_0x110cb5;},'RnsXS':_0x87681a(0x3b2),'PpXEb':'video[data-src]'};document[_0x87681a(0x32e)](_0x2a09a1[_0x87681a(0x444)])['forEach'](_0x1d7ea9=>{const _0x57ca23=_0x87681a,_0x4085b6={'dbcqi':function(_0x1b1929,_0x1e1431){const _0x234b07=_0x47ec;return _0x2a09a1[_0x234b07(0x39e)](_0x1b1929,_0x1e1431);}},_0x4178ba=_0x1d7ea9['dataset'][_0x57ca23(0x434)];if(_0x4178ba&&_0x4178ba['includes'](_0x2a09a1[_0x57ca23(0x496)]))setupVideo(_0x1d7ea9,_0x4178ba);else _0x4178ba&&(_0x57ca23(0x43e)===_0x57ca23(0x45f)?_0x4085b6[_0x57ca23(0x47d)](_0x1ab459[_0x57ca23(0x361)],_0x551c17[_0x57ca23(0x22f)])&&(_0x365e67[_0xd50ae2[_0x57ca23(0x361)]][_0x57ca23(0x3f9)]=!![]):_0x1d7ea9[_0x57ca23(0x434)]=_0x4178ba);});}function retakeQuiz(){const _0x49e941=_0x3c9c61,_0x5d020d={'YhpmC':function(_0x268828,_0x5c8e2f){return _0x268828(_0x5c8e2f);},'ArZvE':_0x49e941(0x4a4),'OtDbl':function(_0x1b2632,_0x46554a){return _0x1b2632===_0x46554a;},'LaiVf':_0x49e941(0x32d),'hcOHW':'MrPXm','TrHGt':'custom_quiz.html','NNYvn':'customQuizData'};_0x5d020d[_0x49e941(0x254)](confirm,_0x5d020d[_0x49e941(0x25b)])&&(_0x5d020d[_0x49e941(0x482)](_0x5d020d[_0x49e941(0x2f9)],_0x5d020d[_0x49e941(0x244)])?_0x41b22d[_0x1cbde2[_0x49e941(0x361)]]['bookmarked']=!![]:(window[_0x49e941(0x407)][_0x49e941(0x280)]['endsWith'](_0x5d020d[_0x49e941(0x21a)])&&localStorage[_0x49e941(0x35f)](_0x5d020d[_0x49e941(0x410)]),location['reload']()));}function loadBookmarkedQuestions(){const _0x1e2490=_0x3c9c61,_0xdcf3af={'esLaR':function(_0x283634,_0x7dad0a){return _0x283634<_0x7dad0a;},'DGYqI':_0x1e2490(0x423)},_0x5921ef=JSON[_0x1e2490(0x3ef)](localStorage['getItem'](_0xdcf3af['DGYqI']))||[];_0x5921ef['forEach'](_0x44b857=>{const _0x50063d=_0x1e2490;_0x44b857['quizFile'][_0x50063d(0x2c7)](quizName[_0x50063d(0x277)]()[_0x50063d(0x357)](/ /g,'-'))&&(_0xdcf3af[_0x50063d(0x3e3)](_0x44b857[_0x50063d(0x361)],questionsData[_0x50063d(0x22f)])&&(questionStates[_0x44b857['questionIndex']][_0x50063d(0x3f9)]=!![]));});}function _0x421b(){const _0x4862ce=['questionText','erSDa','IXdWi','bCNgz','DOMContentLoaded','ZVmdm','Which\x20of\x20the\x20following\x20is\x20a\x20true\x20statement\x20regarding\x20Pretomanid?','none','pOyiu','SWTDY','back','<p><strong>Metformin</strong>\x20is\x20known\x20to\x20cause\x20<strong>unexplained\x20diarrhoea</strong>\x20as\x20its\x20adverse\x20effect.</p>\x0a<p><strong>Metformin</strong>\x20is\x20a\x20member\x20of\x20the\x20<strong>biguanide</strong>\x20class\x20of\x20oral\x20hypoglycemic\x20drugs.\x20It\x20acts\x20by\x20primarily\x20by\x20inhibiting\x20<strong>hepatic\x20gluconeogenesis</strong>.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>It\x20activates\x20<strong>AMP-dependent\x20protein\x20kinase</strong>,\x20</span>leading\x20to\x20stimulation\x20of\x20hepatic\x20fatty\x20acid\x20oxidation,\x20glucose\x20uptake,\x20and\x20nonoxidative\x20glucose\x20metabolism\x20and\x20reduction\x20of\x20lipogenesis\x20and\x20gluconeogenesis.\x20It\x20also\x20appears\x20to\x20act\x20in\x20the\x20gut.</p>\x0a<p>Metformin\x20is\x20accepted\x20as\x20the\x20first-line\x20treatment\x20of\x20<strong>type\x202\x20diabetes</strong>\x20and\x20is\x20the\x20most\x20commonly\x20used\x20oral\x20agent\x20for\x20this\x20condition.\u00a0It\x20has\x20been\x20used\x20as\x20a\x20treatment\x20of\x20infertility\x20in\x20women\x20with\x20<strong>polycystic\x20ovarian\x20syndrome</strong>.</p>\x0a<p>The\x20most\x20common\x20<strong>side\x20effects</strong>\x20of\x20metformin\x20are\x20<strong>gastrointestinal</strong>:\x20nausea,\x20indigestion,\x20<strong>abdominal\x20cramps,\x20</strong>bloating,\x20and\x20<strong>diarrhea</strong>.\x20The\x20use\x20of\x20metformin\x20is\x20also\x20associated\x20with<strong>\u00a0lower\x20blood\x20levels\x20of\x20vitamin\x20B12.</strong></p>\x0a<p>Most\x20adverse\x20GI\x20effects\x20of\x20metformin\x20abate\x20over\x20time\u00a0and\x20can\x20be\x20minimized\x20by\x20<strong>starting\x20at\x20a\x20low\x20dose</strong>\x20and\x20gradually\x20titrating\x20to\x20a\x20target\x20dose\x20over\x20several\x20weeks,\x20as\x20well\x20as\x20by\x20having\x20patients\x20take\x20the\x20drug\x20<strong>with\x20meals</strong>.\x20<strong>Extended-release</strong>\x20metformin\x20has\x20decreased\x20GI\x20side\x20effects\x20and\x20can\x20be\x20substituted\x20for\x20immediate-release\x20metformin.\x20<strong>Lactic\x20acidosis</strong>\x20has\x20been\x20linked\x20with\x20the\x20use\x20of\x20metformin.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A\x20-\x20<strong>Sitagliptin</strong>\x20is\x20a\x20dipeptidyl\x20peptidase-4\x20inhibitor.\x20Its\x20use\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20<strong>heart\x20failure</strong>.</p>\x0a<p>Option\x20C\x20-\x20<strong>Glimepiride\x20</strong>belongs\x20to\x20the\x20class\x20of\x20sulfonylureas.\x20It\x20stimulates\x20insulin\x20release\x20by\x20inhibiting\x20the\x20activity\x20of\x20the\x20β\x20cell\x20KATP\x20channel\x20complex.\x20Its\x20side\x20effects\x20include\x20<strong>hypoglycemia</strong>,\x20and\x20<strong>weight\x20gain.</strong></p>\x0a<p>Option\x20D\x20-\x20<strong>Pioglitazone</strong>\x20is\x20an\x20activator\x20of\x20the\x20peroxisome\x20proliferator-activated\x20receptor\x20γ\x20(PPARγ),\x20which<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>\x20is\x20involved\x20in\x20the\x20regulation\x20of\x20genes\x20related\x20to\x20glucose\x20and\u00a0</span>lipid\x20metabolism.\x20Its\x20adverse\x20effects\x20include\x20increased\x20incidence\x20of\x20<strong>heart\x20failure</strong>,\x20<strong>peripheral\x20edema</strong>,\x20weight\x20gain,\x20<strong>macular\x20edema</strong>,\x20and\x20<strong>osteoporosis</strong>.</p>','jiTrX','QAnde','PRmmf','No\x20question\x20text\x20available','stringify','A\x20young\x20female\x20weighing\x2046\x20kg\x20is\x20on\x20digoxin\x20with\x20vd-6\x20L/kg\x20and\x20clearance\x204.6\x20L/h.\x20Calculate\x20the\x20half-life\x20of\x20digoxin.','HiLio','hMJCk','iClxb','lXzDx','vjoAN','LaiVf','SGLT2\x20inhibitor','Necitumumab','HSXKR','not-attempted','avgTimeResult','UfEyT','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','optionsContainer','Bromhexine\x20as\x20it\x20liquifies\x20sputum','submitSection','a-iii,\x20b-i,\x20c-iv,\x20d-ii','table','test','ewEMv','PMzEA','Unstable\x20angina','TlHAw','selectedAnswer','Pablociclib','UGXNF','gzsvd','vKxqZ','gzfvA','warn','SjOoo','XWOZV','kaege','kZwqC','a-i,\x20b-ii,\x20c-iii,\x20d-iv','RtEoc','return\x20(function()\x20','pZCsD','correct_choice_id','HNkHd','DnVwF','CGefc','CwEtd','IHbtj','MgnHq','oRwNd','VPMDS','add','ERfrN','bOojB','Which\x20of\x20the\x20following\x20medications\x20used\x20in\x20treating\x20leprosy\x20causes\x20skin\x20pigmentation?','OqQET','TtLVt','choices','<p>Coagulation\x20profile\x20monitoring\x20is\x20required\x20while\x20using\x20<strong>lepirudin</strong>.</p>\x0a<p><strong>Lepirudin</strong>\x20is\x20a<strong>\x20parenteral\x20direct\x20thrombin\x20inhibitor</strong>,\x20which\x20is\x20a\x20recombinant\x20form\x20of\x20hirudin\x20extracted\x20from\x20the\x20saliva\x20of\x20leech.\x20Its\x20action\x20is\x20independent\x20of\x20anti-thrombin,\x20which\x20means\x20it\x20can\x20reach\x20and\x20inactivate\x20fibrin-bound\x20thrombin\x20in\x20thrombi.\u00a0It\x20is\x20excreted\x20by\x20the\x20<strong>kidney</strong>\x20and\x20should\x20be\x20used\x20with\x20great\x20caution\x20in\x20patients\x20with\x20renal\x20insufficiency\x20as\x20no\x20antidote\x20exists.\u00a0</p>\x0a<p>Like\x20heparin,\x20lepirudin\x20must\x20be\x20administered\x20parenterally\x20and\x20is\x20monitored\x20by\x20<strong>aPTT</strong>.\x20Lepirudin\x20was\x20approved\x20for\x20use\x20in\x20patients\x20with\x20thrombosis\x20related\x20to\x20heparin-induced\x20thrombocytopenia\x20(HIT).\x20Its\x20production\x20was\x20discontinued\x20by\x20the\x20manufacturer\x20in\x202012.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B\x20-\x20<strong>Enoxaparin</strong>\x20is\x20a\x20low\x20molecular\x20weight\x20heparin\x20(LMWH)\x20that\x20inhibits\x20activated\x20factor\x20X\x20with\x20less\x20effect\x20on\x20thrombin.\x20Hence,\x20it\x20has\x20a\x20smaller\x20effect\x20on\x20the\x20coagulation\x20profile\x20and\x20<strong>does\x20not\x20need\x20monitoring</strong>.\u00a0</p>\x0a<p>Option\x20C\x20-\x20<strong>Fondaparinux</strong>\x20avidly\x20binds\x20antithrombin,\x20resulting\x20in\x20efficient\x20inactivation\x20of\x20factor\x20Xa.\x20It\x20is\x20effective\x20in\x20the\x20prevention\x20and\x20treatment\x20of\x20venous\x20thromboembolism\x20and\x20does\x20not\x20appear\x20to\x20cross-react\x20with\x20pathologic\x20HIT\x20antibodies\x20in\x20most\x20individuals.\x20Like\x20LMWH,\x20it\x20<strong>does\x20not\x20require\x20monitoring</strong>\x20of\x20the\x20coagulation\x20profile.</p>\x0a<p>Option\x20D\x20-\x20<strong>Dabigatran</strong>\x20is\x20an\x20oral\x20direct\x20thrombin\x20inhibitor\x20approved\x20for\x20the\x20reduction\x20in\x20risk\x20of\x20stroke\x20and\x20systemic\x20embolism\x20with\x20nonvalvular\x20atrial\x20fibrillation,\x20treatment\x20of\x20venous\x20thromboembolism\x20(VTE)\x20and\x20VTE\x20prophylaxis\x20following\x20hip\x20or\x20knee\x20replacement\x20surgery.\x20It\x20<strong>does\x20not\x20require\x20monitoring</strong>\x20of\x20coagulation\x20profile.</p>','<p><strong>Evolocumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20acts\x20by\x20<strong>inhibiting\x20PCSK9</strong>.</p>\x0a<p><strong>PCSK9</strong>\x20(proprotein\x20convertase\x20subtilisin/kexin\x20type)\x20is\x20a\x20serine\x20protease\x20that\x20causes\x20lysosomal\x20<strong>degradation</strong>\x20of\x20the\x20low-density\x20lipoprotein\x20(<strong>LDL</strong>)\x20<strong>receptors</strong>\x20present\x20on\x20hepatocytes.\x20Monoclonal\x20antibodies\x20against\x20PCSK9\x20such\x20as\x20<strong>alirocumab</strong>\x20and\x20<strong>evolocumab</strong>\x20counter\x20this\x20and\x20cause\x20persistence\x20of\x20LDL\x20receptors\x20on\x20hepatocytes.\x20This\x20leads\x20to<strong>\x20more\x20LDL\x20uptake</strong>\x20from\x20the\x20circulation,\x20bringing\x20down\x20the\x20LDL-cholesterol\x20levels.</p>\x0a<p>Evolocumab\x20is\x20administered\x20as\x20a\x20140-mg\x20injection\x20every\x202\x20weeks\x20or\x20as\x20a\x20420-mg\x20injection\x20once\x20a\x20month.\x20PCKS9\x20inhibitors\x20should\x20not\x20be\x20used\x20in\x20pregnancy\x20because\x20transmission\x20across\x20the\x20placenta\x20is\x20expected.</p>\x0a<p>PCSK9\x20inhibitors\x20are\x20indicated\x20only\x20as\x20<strong>adjunctive\x20therapy</strong>\x20in\x20patients\x20with\x20<strong>familial\x20hypercholesterolemia</strong>(FH)\x20or\x20established\x20<strong>atherosclerotic\x20cardiovascular\x20disease</strong>(ASCVD)\x20who\x20have\x20elevated\x20LDL-cholesterol\x20levels\x20despite\x20being\x20on\x20maximum\x20statin\x20therapy.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A\x20-\u00a0<strong>Bempedoic\x20acid\x20</strong>acts\x20by\x20inhibiting\x20<strong>de\x20novo</strong>\x20hepatocyte\x20<strong>cholesterol\x20biosynthesis</strong>,\x20by\x20blocking\x20the\x20enzyme\x20<strong>adenosine</strong>\x20<strong>triphosphate\x20citrate\x20lyase</strong>.\x20The\x20drug\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy\x20to\x20further\x20lower\x20LDL-C\x20in\x20patients\x20with\x20FH\x20or\x20established\x20ASCVD.</p>\x0a<p>Option\x20B\x20-\u00a0<strong>Lomitapide</strong>\x20acts\x20by\x20inhibiting\x20<strong>microsomal\x20triglyceride\x20transfer\x20protein</strong>\x20(MTP),\x20which\x20is\x20essential\x20for\x20the\x20intracellular\x20transfer\x20of\x20triglycerides\x20into\x20triglyceride-rich\x20lipoproteins,\x20thus\x20inhibiting\x20the\x20formation\x20of\x20<strong>VLDLs</strong>\x20in\x20hepatocytes\x20and\x20<strong>chylomicrons</strong>\x20in\x20intestinal\x20epithelial\x20cells.\u00a0It\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20for\x20lowering\x20LDL-C\x20levels,\x20total\x20cholesterol,\x20apo\x20B,\x20and\x20non–HDL\x20lipoproteins\x20in\x20patients\x20with\x20FH.</p>\x0a<p>Option\x20C\x20-\u00a0<strong>Ezetimibe</strong>\x20inhibits\x20luminal\x20cholesterol\x20uptake\x20by\x20jejunal\x20enterocytes,\x20by\x20inhibiting\x20<strong>Niemann-Pick\x20C1–like\x201\x20transport</strong>\x20protein.\x20The\x20role\x20of\x20ezetimibe\x20as\x20monotherapy\x20for\x20patients\x20with\x20elevated\x20LDL-C\x20levels\x20is\x20generally\x20limited\x20to\x20a\x20small\x20group\x20of\x20statin-intolerant\x20patients.</p>','DSnST','SCwSy','querySelectorAll','JyKDf','bCHOF','JdLZl','DoYVx','A\x20patient\x20presents\x20with\x20complaints\x20of\x20a\x20cough\x20producing\x20tenacious\x20white\x20sputum.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20about\x20the\x20drug\x20that\x20could\x20be\x20prescribed\x20for\x20this\x20condition?','cEjqc','TWBgT','mLhxG','open','A\x20patient\x20known\x20case\x20of\x20diabetes,\x20shows\x20microalbuminuria\x20on\x20urine\x20analysis,\x20done\x20twice\x20at\x20an\x20interval\x20of\x206\x20months.\x20Renal\x20function\x20tests\x20are\x20normal.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20not\x20useful\x20in\x20preventing\x20the\x20progression\x20of\x20renal\x20damage?','3,4','yEzxb','NnuXj','Bookmark','eNRBq','YCrWa','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','fbGxt','incorrectResult','performanceModal','block','style','PexVA','WirUb','MqKKY','GIfiX','OIGyC','ZGRWo','ArrowRight','Coagulation\x20profile\x20monitoring\x20is\x20required\x20for\x20which\x20of\x20the\x20following\x20drugs?','solutionText','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','incorrectCount','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','106623XXGNRR','vbcBo','Pvtfe','mmBbl','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','JQXTI','replace','yKlXQ','059\x20Pharmacology\x20Ini-Cet\x202024','XwsLt','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','min','sQcgd','totalQuestionsResult','removeItem','Pramipexole','questionIndex','border-green-500','modTe','navBtn_','6LmfNof','Pertuzumab','pop','<p>The\x20correct\x20set\x20of\x20matching\x20is<strong>\u00a0a-ii,\x20b-iii,\x20c-i,\x20d-iv.</strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2034.3013%;\x20height:\x2089.5936px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>a.\x20Naloxone</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>ii.\x20Opioid\x20overdose</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>b.\x20Oxazepam</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>iii.\x20Delirium\x20tremens</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>c.\x20Varenicline</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>i.\x20Smoking\x20cessation</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>d.\x20Acamprosate</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>iv.\x20Treatment\x20of\x20alcoholism</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Naloxone</strong>\x20is\x20an\x20<strong>opioid\x20antagonist\x20</strong>used\x20to\x20reverse\x20the\x20effects\x20of\x20<strong>opioid\x20overdose</strong>,\x20such\x20as\x20respiratory\x20depression.</p>\x0a<p><strong>Oxazepam</strong>\x20is\x20a\x20<strong>benzodiazepine</strong>\x20used\x20for\x20the\x20management\x20of\x20<strong>delirium\x20tremens</strong>,\x20a\x20severe\x20alcohol\x20withdrawal\x20syndrome.</p>\x0a<p><strong>Varenicline</strong>\x20is\x20a\x20<strong>partial\x20agonist\x20</strong>at\x20the\x20<strong>nicotinic\x20acetylcholine\x20receptors,</strong>\x20used\x20for\x20<strong>smoking\x20cessation</strong>\x20by\x20reducing\x20withdrawal\x20symptoms\x20and\x20cravings.</p>\x0a<p><strong>Acamprosate</strong>\x20is\x20a\x20<strong>modulator\x20</strong>of\x20<strong>glutamate</strong>\x20and\x20<strong>GABA\x20neurotransmission</strong>,\x20used\x20for\x20the\x20treatment\x20of\x20<strong>alcoholism</strong>\x20by\x20reducing\x20cravings\x20and\x20the\x20risk\x20of\x20relapse\x20in\x20alcohol\x20abstinence.</p>','explanation_audio_hin','\x22\x20data-src=\x22','rOsWE','explanation_audio_eng','RoLem','Not\x20Attempted','<div\x20class=\x22mt-4\x22><img\x20src=\x22','gHxqd','ZRSzr','text','aaxrK','These\x20complications\x20can\x20be\x20minimized\x20by\x20administering\x20fosphenytoin\x20at\x20a\x20rate\x20of\x20less\x20than\x20250\x20mg\x20of\x20phenytoin\x20sodium\x20equivalents\x20per\x20minute','custom_quiz.html','A\x20patient\x20is\x20set\x20to\x20receive\x20intermittent\x20treatment\x20with\x20teriparatide.\x20Which\x20of\x20the\x20following\x20complications\x20does\x20this\x20drug\x20predispose\x20him\x20to?','iUkwl','Iron\x20requirement\x20can\x20be\x20fulfilled\x20in\x20single\x20dose','createElement','Osteosarcoma','Which\x20of\x20the\x20following\x20drugs\x20act\x20on\x20sodium\x20channels\x20and\x20potentiate\x20slow\x20sodium\x20inactivation?','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','NposK','YzfoO','AbZet','statsBar','UpDXM','cunCt','<p><strong>Pertuzumab</strong>\x20is\x20a\x20humanized\x20IgG1\x20monoclonal\x20antibody\x20directed\x20against\x20<strong>HER2</strong>.\u00a0</p>\x0a<p>Pertuzumab\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20HER2-positive,\x20locally\x20advanced,\x20inflammatory,\x20or\x20early-stage\x20<strong>breast\x20cancer</strong>\x20in\x20combination\x20with\x20trastuzumab\x20and\x20docetaxel.\x20Its\x20adverse\x20effect\x20includes\x20<strong>cardiotoxicity</strong>.</p>\x0a<p>The\x20other\x20three\x20antibodies\x20act\x20against\x20<strong>epidermal\x20growth\x20factor\x20receptor</strong>\x20(EGFR)/\x20<strong>HER-1</strong>.\u00a0</p>\x0a<p>Option\x20B\x20-\x20Cetuximab\x20is\x20used\x20to\x20treat\x20patients\x20with\x20metastatic\x20colon\x20cancers\x20and\x20head\x20and\x20neck\x20squamous\x20cell\x20carcinoma\x20(HNSCC).</p>\x0a<p>Option\x20C\x20-\x20Panitumumab\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20EGFR-expressing\x20metastatic\x20colorectal\x20cancer.</p>\x0a<p>Option\x20D\x20-\x20Necitumumab\x20is\x20approved\x20for\x20first-line\x20treatment\x20of\x20patients\x20with\x20metastatic,\x20squamous\x20non-small\x20cell\x20lung\x20cancer\x20in\x20combination\x20with\x20gemcitabine\x20and\x20cisplatin.</p>','ovIgc','markedForReview','Which\x20drug\x20acts\x20on\x20the\x20marked\x20receptor?','oGuoW','BYQLA','SaVKP','Fgrrc','RzPaA','bTNlL','QJMir','JdUYv','A\x2060-year-old\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20hypertension\x20and\x20diabetes\x20underwent\x20PCI\x20stent\x20placement\x20for\x20NSTEMI\x20last\x20year.\x20He\x20is\x20currently\x20on\x20aspirin,\x20metoprolol\x20and\x20atorvastatin.\x20He\x20comes\x20for\x20a\x20follow-up,\x20and\x20his\x20lipid\x20profile\x20is\x20as\x20follows-\x20Total\x20cholesterol\x20252mg/dl\x20LDL:\x20156mg/dl,\x20triglyceride\x20158mg/dl\x20and\x20HDL-\x2040\x20mg/dl.\x20Which\x20drugs\x20can\x20be\x20added\x20based\x20on\x20his\x20lipid\x20profile?','XSNcO','log','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','mcckv','get','lYIuM','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','Stiripentol','{}.constructor(\x22return\x20this\x22)(\x20)','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','xTXOO','getItem','isArray','toString','yQzoq','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','YnUSe','YRNJQ','Hvchj','trace','Felbamate','48uAMQbM','CSmFj','padStart','eCSIr','XorwY','tUgJu','HsaUd','RVSmf','UNfDS','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','TDSoT','kGstP','reload','.m3u8','forEach','data-option-index','JKxLd','NhBwQ','zvYjv','47247yYnbzA','Fosamprenavir','<p>In\x20the\x20given\x20scenario,\x20the\x20woman\x20requires\x20<strong>suppression\x20of\x20lactation</strong>,\x20for\x20which\x20<strong>cabergoline</strong>\x20is\x20indicated.</p>\x0a<p>In\x20the\x20postpartum\x20period,\x20prolactin\x20promotes\x20lactation.\x20<strong>Dopamine</strong>(DA)\x20is\x20the\x20primary\x20regulator\x20of\x20prolactin\x20secretion\x20from\x20the\x20pituitary\x20gland.\x20DA\x20released\x20from\x20the\x20hypothalamus\x20into\x20the\x20hypophyseal\x20portal\x20blood\x20supply\x20acts\x20on\x20lactotroph\x20<strong>D2\x20receptors</strong>\x20to\x20<strong>decrease\x20prolactin</strong>\x20secretion.\x20The\x20DA\x20agonists\x20like\x20bromocriptine\x20and\x20cabergoline\x20are\x20used\x20in\x20conditions\x20requiring\x20suppression\x20of\x20prolactin.</p>\x0a<p><strong>Cabergoline</strong>\x20is\x20an\x20<strong>ergot\x20derivative</strong>\x20with\x20a\x20longer\x20t1/2\x20(~65\x20h),\x20higher\x20affinity,\x20and\x20greater\x20selectivity\x20for\x20the\x20DA\x20D2\x20receptor\x20compared\x20to\x20bromocriptine.\x20Cabergoline\x20is\x20the\x20preferred\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>hyperprolactinemia\x20</strong>because\x20of\x20greater\x20efficacy\x20and\x20lower\x20adverse\x20effects.\x20Therapy\x20is\x20initiated\x20at\x20a\x20dose\x20of\x200.25\x20mg\x20twice\x20a\x20week\x20or\x200.5\x20mg\x20once\x20a\x20week.\x20Cabergoline\x20induces\x20remission\x20in\x20a\x20significant\x20number\x20of\x20patients\x20with\x20<strong>prolactinomas</strong>.\x20At\x20higher\x20doses,\x20cabergoline\x20is\x20used\x20in\x20some\x20patients\x20with\x20acromegaly\x20alone\x20or\x20in\x20conjunction\x20with\x20somatostatin\x20analogs.</p>\x0a<p>Adverse\x20Effects\x20-\u00a0</p>\x0a<p>Compared\x20to\x20bromocriptine,\x20cabergoline\x20has\x20a\x20much\x20lower\x20tendency\x20to\x20induce\x20nausea,\x20although\x20it\x20still\x20may\x20cause\x20hypotension\x20and\x20dizziness.\x20Cabergoline\x20has\x20been\x20linked\x20to\x20<strong>valvular\x20heart\x20disease</strong>,\x20an\x20effect\x20proposed\x20to\x20reflect\x20agonist\x20activity\x20at\x20the\x20serotonin\x205HT2B\x20receptor.\u00a0However,\x20this\x20effect\x20is\x20seen\x20primarily\x20at\x20the\x20high\x20doses\x20used\x20in\x20patients\x20being\x20treated\x20for\x20Parkinson\x27s\x20disease\x20and\x20is\x20not\x20seen\x20in\x20the\x20conventionally\x20used\x20doses\x20(≤2\x20mg/week)\x20for\x20patients\x20with\x20prolactinomas.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B\x20-\x20<strong>Sumatriptan</strong>\x20is\x20a\x20<strong>5HT1B/1D\x20receptor\x20agonist</strong>\x20used\x20in\x20the\x20treatment\x20of\x20acute\x20attacks\x20of\x20<strong>migraine</strong>.</p>\x0a<p>Option\x20C\x20-\x20<strong>Chlorpromazine</strong>\x20is\x20a\x20<strong>typical\x20antipsychotic</strong>,\x20which\x20has\x20<strong>D2\x20antagonistic</strong>\x20activity.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>schizophrenia</strong>,\x20<strong>acute\x20mania</strong>,\x20and\x20refractory\x20<strong>nausea\x20and\x20vomiting</strong>.\x20<strong>Hyperprolactinemia</strong>\x20is\x20an\x20<strong>adverse\x20effect</strong>\x20associated\x20with\x20its\x20use.</p>\x0a<p>Option\x20D\x20-\x20<strong>Pramipexole</strong>\x20is\x20a\x20<strong>non-ergot\x20alkaloid</strong>\x20with\x20a\x20broader\x20DA\x20receptor\x20agonist\x20activity,\x20with\x20the\x20highest\x20affinity\x20to\x20<strong>D3</strong>\x20receptors.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>Parkinson\x27s\x20disease</strong>\x20and\x20<strong>restless\x20leg\x20syndrome</strong>.\x20It\x20is\x20not\x20indicated\x20for\x20the\x20treatment\x20of\x20breast\x20engorgement.</p>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','qhfpE','qzASF','Given\x20in\x20all\x20patients\x20with\x20seizures\x20regardless\x20of\x20cardiac\x20arrhythmias,\x20hypotension\x20and/or\x20CNS\x20depression','4473174RQKFrN','toggle','nav-btn-marked-review','ZggaY','mRrfe','xxDKJ','tSvzB','markReviewBtn','correctResult','a-iv,\x20b-ii,\x20c-iii,\x20d-i','classList','dLZcD','solutionAudio','explanationVideoPlayer','dataset','<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2046.851%;\x20height:\x20134.39px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Antiepileptic\x20Drugs</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Mechanism\x20of\x20Action</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p><strong>Phenytoin\x20(Option\x20A)</strong></p>\x0a<p>Carbamazepine</p>\x0a<p><strong>Lamotrigine\x20(Option\x20B)</strong></p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Inhibit\x20Na\x20channels</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p>Phenobarbital</p>\x0a<p>Vigabatrin</p>\x0a<p>Tiagabine</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>Enhance\x20GABA\x20inhibition</p>\x0a<p>Vigabatrin\x20–\x20block\x20GABA\x20aminotransferase\x20irreversibly</p>\x0a<p>Tiagabine\x20–\x20block\x20GABA\x20reuptake</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p>Ethosuximide</p>\x0a<p>Zonisamide</p>\x0a<p>Gabapentin</p>\x0a<p>Pregabalin</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>Block\x20Ca\x20channels</p>\x0a<p>Ethosuximide,\x20Zonisamide\x20–block\x20T-type\x20Ca\x20channels</p>\x0a<p>Gabapentin,\x20Pregabalin\x20–block\x20voltage\x20sensitive\x20Ca\x20channels</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Levetiracetam</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Binds\x20synaptic\x20vesicle\x20protein\x202A</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Valproate</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>\u00a0Multiple\x20MOA:</p>\x0a<p>GABA\x20related\x20action</p>\x0a<p>NMDA\x20receptor\x20antagonist</p>\x0a<p>Histone\x20deacetylase\x20inhibitor</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22><strong>Topiramate\x20(Option\x20D)</strong></td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>Multiple\x20MOA:</p>\x0a<p>GABAergic\x20action</p>\x0a<p>AMPA\x20receptor\x20antagonist</p>\x0a<p>Acts\x20on\x20Na,\x20Ca\x20and\x20K\x20channels</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22>Drugs\x20acting\x20on\x20glutamate\x20receptors</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>NMDA-type\x20glutamate\x20receptors:</p>\x0a<p>Valproate,\x20Felbamate</p>\x0a<p>AMPA-type\x20glutamate\x20receptors:</p>\x0a<p>Topiramate,\x20Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22>\x0a<p>Newer\x20drugs:Rufinamide\u00a0</p>\x0a<p>Lacosamide\x20\u00a0\x20\u00a0</p>\x0a<p>Ezogabine\x20\u00a0</p>\x0a<p>Perampanel</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>Prolongs\x20inactivation\x20of\x20voltage-gated\x20Na\x20channels\x20\u00a0\x20Enhances\x20inactivation\x20of\x20voltage-gated\x20Na\x20channels\x20Inhibits\x20collapsin\x20response\x20mediator\x20protein\x202\x20\u00a0</p>\x0a<p>Potassium\x20channel\x20opener\x20\u00a0</p>\x0a<p>AMPA-type\x20glutamate\x20receptor\x20antagonist</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>\u00a0</p>','<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Ganaxolone</strong>\x20is\x20a\x20recently\x20approved\x20drug\x20for\x20the\x20treatment\x20of\x20seizures\x20associated\x20with\x20CDKL5\x20deficiency.\x20The\x20exact\x20mechanism\x20of\x20action\x20of\x20Ganaxolone\x20is\x20unknown,\x20but\x20its\x20anticonvulsant\x20effects\x20are\x20thought\x20to\x20result\x20from\x20positive\x20allosteric\x20modulation\x20of\x20the\x20GABA-A\x20receptor\x20in\x20the\x20CNS.\x20It\x20can\x20be\x20used\x20in\x20adults\x20as\x20well\x20as\x20children\x20older\x20than\x202\x20years\x20of\x20age.\x20The\x20most\x20common\x20adverse\x20reactions\x20associated\x20with\x20the\x20drug\x20are\x20somnolence,\x20pyrexia,\x20salivary\x20hypersecretion\x20and\x20seasonal\x20allergy.\u00a0</p>\x0a<p>Option\x20C:\x20<strong>Felbamate</strong>\x20is\x20the\x20NMDA\x20receptor\x20antagonist\x20prescribed\x20to\x20this\x20patient.\x20It\x20also\x20potentiates\x20GABA\x20action.\x20It\x20is\x20indicated\x20in\x20refractory\x20primary\x20or\x20secondary\x20generalised\x20seizures\x20and\x20Lennox-Gastaut\x20syndrome.\x20Felbamate\x20is\x20associated\x20with\x20aplastic\x20anemia\x20and\x20liver\x20failure.</p>\x0a<p>Option\x20D:\x20<strong>Stiripentol</strong>\x20is\x20a\x20GABA\x20A\x20receptor\x20modulator\x20with\x20GABA-enhancing\x20activity.\x20It\x20is\x20clinically\x20used\x20in\x20conjunction\x20with\x20valproate\x20and\x20clobazam\x20for\x20refractory\x20generalized\x20tonic-clonic\x20seizures\x20with\x20severe\x20myoclonic\x20epilepsy\x20in\x20infants\x20(Dravet\x20syndrome).</p>','correctCount','Which\x20of\x20the\x20following\x20acts\x20by\x20suicide\x20inhibition?','lNmbq','JcyqH','Pioglitazone','IOoRg','szUAK','pGQhJ','UFUmf','questions','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','Lomitapide','SBAYo','MPEyu','grKqj','Pharmacology','exception','xxXJR','\x22\x20data-option-index=\x22','esLaR','getElementById','Given\x20in\x20XDR\x20TB\x20with\x20Bedaquiline\x20and\x20Linezolid','gnOwB','BszMO','bind','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','width','tLjmI','fSAUc','LROXG','Fondaparinux','parse','-600\x20text-white\x22>','hidden','<p><strong>Dapagliflozin</strong>\x20is\x20known\x20to\x20cause\x20<strong>urinary\x20tract\x20infections</strong>.</p>\x0a<p>Dapagliflozin\x20is\x20a\x20sodium-glucose\x20transporter\x202\x20(<strong>SGLT-2</strong>)\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20the\x20SGLT-2\x20transporter\x20which\x20is\x20present\x20on\x20the\x20proximal\x20segment\x20of\x20the\x20renal\x20tubule\x20and\x20is\x20responsible\x20for\x20the\x20reabsorption\x20of\x2080-90%\x20of\x20filtered\x20glucose.\x20This\x20results\x20in\x20<strong>glycosuria</strong>.\x20Other\x20SGLT-2\x20inhibitors\x20include\x20canagliflozin\x20and\x20empagliflozin.</p>\x0a<p>Apart\x20from\x20their\x20effect\x20on\x20lowering\x20blood\x20glucose\x20levels,\x20SGLT2\x20inhibitors\x20can\x20cause\x20mild\x20weight\x20loss\x20and\x20reduction\x20in\x20blood\x20pressure.\x20They\x20have\x20also\x20been\x20shown\x20to\x20reduce\x20the\x20risk\x20of\x20hospitalization\x20in\x20patients\x20with\x20<strong>heart\x20failure</strong>.</p>\x0a<p>The\x20common\x20side\x20effects\x20include\x20<strong>urinary\x20tract\x20infections</strong>\x20and\x20<strong>genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine.\x20There\x20is\x20a\x20risk\x20of\x20the\x20development\x20of\x20<strong>diabetic\x20ketoacidosis</strong>.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B\x20-\x20<strong>Sitagliptin</strong>\x20is\x20a\x20dipeptidyl\x20peptidase-4\x20inhibitor.\x20Its\x20use\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20heart\x20failure.</p>\x0a<p>Option\x20C\x20-\x20<strong>Pioglitazone</strong>\x20is\x20an\x20activator\x20of\x20the\x20peroxisome\x20proliferator-activated\x20receptor\x20γ\x20(PPARγ),\x20which\x20is\x20involved\x20in\x20the\x20regulation\x20of\x20genes\x20related\x20to\x20glucose\x20and\x20lipid\x20metabolism.\x20Its\x20adverse\x20effects\x20include\x20increased\x20incidence\x20of\x20<strong>heart\x20failure</strong>,\x20<strong>peripheral\x20edema</strong>,\x20weight\x20gain,\x20<strong>macular\x20edema</strong>,\x20and\x20<strong>osteoporosis</strong>.</p>\x0a<p>Option\x20D\x20-\x20<strong>Glimepiride</strong>\u00a0belongs\x20to\x20the\x20class\x20of\x20sulfonylureas.\x20It\x20stimulates\x20insulin\x20release\x20by\x20inhibiting\x20the\x20activity\x20of\x20the\x20β\x20cell\x20KATP\x20channel\x20complex.\x20Its\x20side\x20effects\x20include\x20<strong>hypoglycemia</strong>\x20and\x20<strong>weight\x20gain</strong>.</p>','review-question\x20','vWUjP','mptkd','8088642ZvhGZR','green','JNMnU','bookmarked','split','HgMwL','xPZqM','lOTgf','bookmarkText','XgujB','className','answered','EfDRo','rWqQl','push','cHkVb','qGFUX','location','sjANR','wWSyM','izfLa','Only\x201\x20and\x203','totalAttempted','display','Calcitriol','Ezetemibe','NNYvn','textContent','solution','GjGsq','__proto__','not_attempted','Vandetinib','oKUvi','QuKgR','HFUoF','zzSUp','https://dhmbxeygs57ff.cloudfront.net/uploads/3d80b15bec8745fa8ca1a9774dbcf000x1280x361.JPEG','7689496BhVQzU','status','gWsOv','hIBII','TIeZf','osgYD','VlZOn','bookmarkedQuestions','QvkBL','hVoQC','xytka','aBaZk','JyEXr','bNkmP','0.9h','explanation_images','VrLha','fromCharCode','cVkVE','error','LwMKF','modeModal','keMro','target','src','addEventListener','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','42h','Lacosamide','uGThR','Ypqyh','now','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','sMyrl','kvBJs','kvCoW','.option-button','gRzOu','(((.+)+)+)+$','hfILz','PpXEb','hierarchy','<p><strong>Clofazimine</strong>\x20is\x20a\x20<strong>dye</strong>\x20with\x20leprostatic\x20and\x20antiinflammatory\x20properties.The\x20mechanism\x20of\x20antimicrobial\x20activity\x20of\x20clofazimine\x20against\x20mycobacteria\x20appears\x20to\x20be\x20multifactorial\x20and\x20includes\x20<strong>membrane\x20disruption</strong>,\x20inhibition\x20of\x20mycobacterial\x20phospholipase\x20A2,\x20inhibition\x20of\x20microbial\x20K+\x20transport,\x20generation\x20of\x20hydrogen\x20peroxide,\x20interference\x20with\x20the\x20bacterial\x20electron\x20transport\x20chain,\x20and\x20efflux\x20pump\x20inhibition.</p>\x0a<p>Clofazimine\x20is\x20orally\x20active.\x20It\x20<strong>accumulates\x20in\x20macrophages</strong>\x20and\x20gets\x20deposited\x20as\x20<strong>needle-shaped\x20crystals</strong>\x20in\x20many\x20tissues\x20including\x20subcutaneous\x20fat.\u00a0</p>\x0a<p>Clofazimine\x20is\x20used\x20as\x20a\x20component\x20of\x20multidrug\x20therapy\x20(MDT)\x20for\x20<strong>leprosy</strong>.\x20Because\x20of\x20its\x20<strong>anti-inflammatory</strong>\x20properties,\x20it\x20is\x20valuable\x20in\x20<strong>lepra\x20reactions</strong>.\u00a0Occasionally,\x20it\x20is\x20used\x20as\x20a\x20component\x20of\x20a\x20combination\x20regimen\x20for\x20extensive\x20drug\x20resistant\x20TB\x20(<strong>XDR-TB</strong>).\u00a0</p>\x0a<p>Adverse\x20effects\x20-\u00a0</p>\x0a<ul>\x0a<li><strong>Skin</strong>\x20-\x20The\x20major\x20disadvantage\x20is\x20<strong>reddish-black\x20discoloration</strong>\x20of\x20skin,\x20especially\x20on\x20exposed\x20parts.\x20Discoloration\x20of\x20hair\x20and\x20<strong>body\x20secretions\x20</strong>may\x20also\x20occur.\x20Dryness\x20of\x20the\x20skin,\x20itching\x20and\x20scaling\x20are\x20often\x20troublesome.\x20Acneform\x20eruptions\x20and\x20phototoxicity\x20have\x20been\x20noted.\x20<strong>Conjunctival\x20pigmentation</strong>\x20may\x20create\x20cosmetic\x20problems.\u00a0</li>\x0a<li><strong>GI\x20symptoms</strong>\x20-\x20Nausea,\x20anorexia,\x20abdominal\x20pain,\x20weight\x20loss\x20and\x20enteritis\x20with\x20intermittent\x20loose\x20stools\x20can\x20occur,\x20particularly\x20when\x20higher\x20doses\x20are\x20used\x20to\x20control\x20lepra\x20reaction.\x20Deposition\x20of\x20clofazimine\x20crystals\x20in\x20the\x20<strong>intestinal\x20submucosa</strong>\x20may\x20produce\x20gastrointestinal\x20symptoms.\u00a0</li>\x0a</ul>\x0a<p>Clofazimine\x20is\x20to\x20be\x20avoided\x20during\x20early\x20pregnancy\x20and\x20in\x20patients\x20with\x20liver\x20or\x20kidney\x20damage.\u00a0</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A-\x20<strong>Ofloxacin</strong>\x20is\x20a\x20fluroquinolone.\x20As\x20a\x20component\x20of\x20MDT,\x20it\x20has\x20been\x20found\x20to\x20hasten\x20the\x20bacteriological\x20and\x20clinical\x20response,\x20where\x20it\x20is\x20cidal\x20to\x20<em>M.leprae</em>.\x20Its\x20side\x20effects\x20include\x20<strong>nausea</strong>,\x20vomiting,\x20and\x20abdominal\x20discomfort.\x20<strong>CNS\x20side\x20effects</strong>\x20like\x20dizziness,\x20anxiety\x20and\x20insomnia\x20are\x20also\x20seen.\x20<strong>Tendinitis</strong>\x20is\x20another\x20adverse\x20effect\x20seen\x20with\x20the\x20use\x20of\x20fluoroquinolones.</p>\x0a<p>Option\x20B-\x20<strong>Dapsone\x20</strong>exerts\x20its\x20antimicrobial\x20effect\x20by\x20the\x20inhibition\x20of\x20PABA\x20incorporation\x20into\x20folic\x20acid\x20by\x20<strong>folate\x20synthase</strong>.\x20Apart\x20from\x20being\x20used\x20in\x20leprosy,\x20dapsone\x20is\x20also\x20used\x20for\x20the\x20prophylaxis\x20of\x20<em>T.\x20gondii.\x20</em>The\x20anti-inflammatory\x20effects\x20are\x20the\x20basis\x20for\x20therapy\x20of\x20<strong>dermatitis\x20herpetiformis</strong>,\x20linear\x20immunoglobulin\x20A\x20bullous\x20disease,\x20and\x20relapsing\x20chondritis.\x20Mild\x20<strong>hemolytic\x20anemia</strong>\x20is\x20common,\x20especially\x20in\x20those\x20with\x20<strong>G-6-PD\x20deficiency</strong>.\x20Isolated\x20instances\x20of\x20reversible\x20<strong>peripheral\x20neuropathy</strong>,\x20<strong>drug\x20fever</strong>,\x20hematuria,\x20<strong>pruritus</strong>,\x20psychosis,\x20and\x20a\x20variety\x20of\x20skin\x20rashes\x20have\x20been\x20reported.</p>\x0a<p>Option\x20D\x20-\x20<strong>Rifampicin</strong>\x20interrupts\x20RNA\x20synthesis\x20by\x20binding\x20to\x20a\x20subunit\x20of\x20mycobacterial\x20DNA-dependent\x20RNA\x20polymerase.\x20Apart\x20from\x20being\x20used\x20to\x20treat\x20leprosy,\x20it\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>tuberculosis</strong>,\x20<strong>brucellosis</strong>,\x20and\x20prophylaxis\x20of\x20<em>Meningococcal</em>\x20meningitis.\x20<strong>Hepatitis</strong>\x20is\x20a\x20major\x20adverse\x20effect.\x20Other\x20side\x20effects\x20include\u00a0pruritus\x20with\x20rash,\u00a0<strong>redness\x20</strong>and\u00a0watering\x20of\x20eyes,<br\x20/><strong>flu-like</strong>\x20symptoms\x20and\x20abdominal\x20cramps.\x20<strong>Urine</strong>\x20and\x20secretions\x20may\x20become\x20<strong>orange-red</strong>.</p>','laITC','flex','PtuQs','ZMppK','correctAnswers','ExEQy','Osteonecrosis\x20of\x20the\x20jaw\x20bone','<p>The\x20given\x20clinical\x20scenario\x20suggests\x20<strong>chronic\x20kidney\x20disease</strong>\x20secondary\x20to\x20diabetes,\x20and\x20<strong>hydrochlorothiazide</strong>\x20is\x20not\x20useful\x20in\x20preventing\x20the\x20<strong>progression</strong>\x20of\x20<strong>renal\x20damage.</strong></p>\x0a<p><strong>Chronic\x20kidney\x20disease</strong>\x20(CKD)\x20is\x20defined\x20as\x20abnormalities\x20of\x20kidney\x20structure\x20or\x20function,\x20present\x20for\x20a\x20<strong>minimum\x20of\x203\x20months</strong>,\x20with\x20implications\x20for\x20health.\x20CKD\x20is\x20classified\x20based\x20on\x20cause,\x20glomerular\x20filtration\x20rate\x20(GFR)\x20category\x20(G1–G5),\x20and\x20albuminuria\x20category\x20(A1–A3).\x20Some\x20of\x20the\x20leading\x20causes\x20of\u00a0\x20CKD\x20are\x20<strong>diabetes</strong>,\x20<strong>hypertension</strong>,\x20glomerulonephritis\x20and\x20polycystic\x20kidney\x20disease.</p>\x0a<p>In\x20patients\x20with\x20diabetes\x20mellitus,\x20often\x20there\x20exists\x20a\x20state\x20of\x20<strong>glomerular\x20hyperfiltration</strong>\x20due\x20to\x20decreased\x20vascular\x20resistance\x20of\x20afferent\x20arterioles\x20and\x20increased\x20vascular\x20resistance\x20of\x20efferent\x20arterioles\x20resulting\x20in\x20increased\x20glomerular\x20hydrostatic\x20pressure.\x20This\x20contributes\x20to\x20the\x20progression\x20of\x20the\x20CKD.</p>\x0a<p>The\x20following\x20drugs\x20have\x20been\x20approved\x20in\x20the\x20management\x20of\x20CKD\x20:</p>\x0a<ul>\x0a<li><strong>Angiotensin-converting\x20enzyme\x20inhibitors\x20/\x20Angiotensin\x20receptor\x20blockers</strong>\x20-\x20These\x20medications\x20appear\x20to\x20slow\x20the\x20rate\x20of\x20decline\x20of\x20kidney\x20function\x20in\x20a\x20manner\x20that\x20extends\x20beyond\x20the\x20reduction\x20of\x20systemic\x20arterial\x20pressure\x20and\x20that\x20involves\x20a\x20reduction\x20in\x20the\x20intraglomerular\x20hyperfiltration\x20and\x20hypertension.\u00a0</li>\x0a<li><strong>Finerenone</strong>\x20-\x20It\x20is\x20a<strong>\x20non\x20steroidal\x20mineralocorticoid\x20receptor\x20antagonist</strong>\x20which\x20decreases\x20proteinuria.\x20It\x20has\x20been\x20approved\x20to\x20reduce\x20the\x20risk\x20of\x20end-stage\x20kidney\x20disease,\x20cardiovascular\x20death,\x20and\x20heart\x20failure\x20in\x20diabetic\x20patients\x20with\x20CKD.</li>\x0a<li><strong>SGLT-2\x20inhibitors\x20</strong>-\x20These\x20drugs\x20inhibit\x20sodium-glucose\x20cotransporter\x20type\x202\x20in\x20the\x20proximal\x20convoluted\x20tubule.\x20By\x20increasing\x20NaCl\x20delivery\x20to\x20the\x20thick\x20ascending\x20limb,\x20gliflozins\x20trigger\x20tubuloglomerular\x20feedback\x20and\x20thereby\x20increase\x20preglomerular\x20vascular\x20resistance\x20and\x20decrease\x20glomerular\x20hypertension.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>This\x20contributes\x20to\x20the\x20effectiveness\x20of\x20gliflozins\x20to\x20prevent\x20diabetic\x20kid</span>ney\x20disease.\u00a0</li>\x0a</ul>','OAQoG','YoMXZ','Bromhexine\x20and\x20Dextromethorphan\x20syrup\x20as\x20they\x20liquify\x20sputum\x20and\x20reduce\x20cough\x20due\x20to\x20antitussive\x20effect','question_video','https://dhmbxeygs57ff.cloudfront.net/uploads/a989056e57504c4fbaed4b616bf3068cx1280x1618.JPEG','antQj','AzCgA','remove','SMJqe','Acute\x20oral\x20overdose\x20results\x20primarily\x20in\x20cerebellar\x20and\x20vestibular\x20symptoms\x20and\x20high\x20doses\x20have\x20been\x20associated\x20with\x20marked\x20cerebellar\x20atrophy','NtwFE','bookmarkBtn','IsLyF','Sitagliptin','eiiTH','floor','qFtiJ','5288FCafBW','uEaBc','TlAEO','vFaIY','DChcF','XsqnM','oTauT','oKPQq','vVgyB','hiblK','lTTxU','reviewQuestionsContainer','scuOt','selected','incorrectAnswers','\x20-\x20Brain\x20And\x20Scalpel','LLtWp','USUBW','rblfX','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','UjDtz','<p>The\x20use\x20of\x20<strong>teriparatide</strong>\x20predisposes\x20an\x20individual\x20to\x20the\x20development\x20of\x20<strong>osteosarcoma</strong>.</p>\x0a<p><strong>Teriparatide</strong>\x20is\x20a\x20<strong>parathormone\x20analog</strong>,\x20which\x20is\x20given\x20as\x20<strong>subcutaneous</strong>\x20injections.\x20Pharmacokinetics\x20and\x20systemic\x20actions\x20of\x20teriparatide\x20on\x20mineral\x20metabolism\x20are\x20the\x20same\x20as\x20for\x20PTH.\x20Its\x20main\x20target\x20of\x20action\x20are\x20the\x20osteoblasts.\u00a0</p>\x0a<p>Teriparatide\x20is\x20administered\x20by\x20<strong>once-daily</strong>\x20subcutaneous\x20injection\x20of\x2020\x20μg\x20into\x20the\x20thigh\x20or\x20abdomen.\x20The\x20site\x20of\x20administration\x20should\x20be\x20rotated,\x20but\x20the\x20time\x20at\x20which\x20the\x20injection\x20is\x20made\x20should\x20be\x20the\x20same\x20each\x20day.</p>\x0a<p>Teriparatide\x20and\x20abaloparatide\x20(PTHrP\x20analog)\x20are\x20the\x20only\x20<strong>anabolic</strong>\x20agents\x20currently\x20available\x20that\x20<strong>increase\x20new\x20bone\x20formation\x20</strong>(option\x20C).\x20Candidates\x20for\x20treatment\x20include\x20<strong>women\x20who\x20have\x20a\x20history\x20of\x20osteoporotic\x20fracture</strong>,\x20who\x20have\x20multiple\x20risk\x20factors\x20for\x20fracture,\x20or\x20who\x20failed\x20or\x20are\x20intolerant\x20of\x20previous\x20osteoporosis\x20therapy.\x20<strong>Men\x20with\x20primary\x20or\x20hypogonadal\x20osteoporosis</strong>\x20are\x20also\x20candidates\x20for\x20treatment\x20with\x20these\x20agents.\u00a0</p>\x0a<p>Adverse\x20effects\x20include\x20<strong>hypercalcemia</strong>,\x20exacerbation\x20of\x20<strong>nephrolithiasis</strong>,\x20and\x20elevation\x20of\x20serum\x20uric\x20acid\x20levels.\x20The\x20development\x20of\x20<strong>osteosarcoma</strong>\x20has\x20been\x20a\x20serious\x20concern\x20in\x20patients\x20treated\x20with\x20teriparatide.\x20It\x20comes\x20with\x20a\x20<strong>black-box\x20warning</strong>,\x20and\x20use\x20should\x20be\x20limited\x20to\x20<strong>no\x20more\x20than\x202\x20years</strong>\x20and\x20avoided\x20in\x20patients\x20who\x20are\x20at\x20increased\x20baseline\x20risk\x20for\x20osteosarcoma\x20(including\x20those\x20with\x20Paget\x20disease\x20of\x20bone,\x20unexplained\x20elevations\x20of\x20alkaline\x20phosphatase,\x20open\x20epiphyses,\x20or\x20prior\x20radiation\x20therapy\x20involving\x20the\x20skeleton).</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Options\x20A\x20and\x20B\x20-\x20<strong>Osteonecrosis\x20of\x20the\x20jaw\x20bone</strong>\x20and\x20<strong>subtrochanteric\x20fractures</strong>\x20are\x20the\x20adverse\x20effects\x20of\x20<strong>bisphosphonates</strong>.</p>','NaRkD','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','notAttempted','HgJMk','uDhbb','wxniU','application/vnd.apple.mpegurl','dbcqi','MsTHJ','Which\x20of\x20the\x20following\x20antidiabetic\x20drugs\x20is\x20known\x20to\x20cause\x20unexplained\x20diarrhea?','HFneU','hWxpq','OtDbl','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','FCxbd','7DqttvP','Given\x20intravenously\x20and\x20gets\x20deposited\x20in\x20adipose\x20tissue\x20therefore\x20less\x20toxic','button','Topiramate','UhRcj','mMUOd','pJMQN','CTJOa','cBFPi','lSnWV','LqchK','PCUDh','ERabR','markReviewText','xuaBB','Kvnpb','RnsXS','tAKeC','Tiagabine','Cannot\x20be\x20given\x20with\x20erythropoietin','JaUiR','XZeGg','IMBCl','Which\x20of\x20the\x20following\x20drugs\x20used\x20in\x20the\x20treatment\x20of\x20diabetes\x20is\x20known\x20to\x20cause\x20urinary\x20tract\x20infections?','vQWbU','innerHTML','prototype','quizFile','Bookmarked','correct','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','study','vZeWh','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','No\x20questions\x20available\x20for\x20this\x20quiz.','qvggc','Which\x20of\x20the\x20following\x20diuretics\x20is\x20matched\x20correctly\x20with\x20its\x20location\x20of\x20action?','uZPhY','nav-btn-current','KnVJP','setItem','Qqqxp','vjeGM','nHTJW','AeouO','MyzIH','apply','JjGwf','explanation_video','ElCTw','3|0|1|5|2|4','rejRF','jPeMI','getAttribute','CKoFP','<p>Inhaled\x20nitric\x20oxide(iNO)\x20is\x20used\x20for\x20<strong>persistent\x20pulmonary\x20hypertension\x20in\x20newborns</strong>.\x20(Option\x20A)</p>\x0a<p><strong>Inhaled\x20NO</strong>\x20selectively\x20<strong>dilates</strong>\x20the\x20<strong>pulmonary\x20vasculature</strong>,\x20hence\x20used\x20in\x20diseases\x20associated\x20with\x20increased\x20pulmonary\x20vascular<strong>\x20</strong>resistance.\x20Inhaled\x20NO\x20is\x20an\x20FDA-approved\x20drug\x20for\x20persistent\x20pulmonary\x20hypertension\x20in\x20the\x20newborn.\u00a0</p>\x0a<p>Inhaled\x20NO\x20can\x20also\x20be\x20used\x20during\x20<strong>cardiac\x20catheterization</strong>\x20to\x20evaluate\x20the\x20<strong>pulmonary\x20vasodilating\x20capacity</strong>\x20of\x20patients\x20with\x20<strong>heart\x20failure</strong>\x20and\x20infants\x20with\x20<strong>congenital\x20heart\x20disease</strong>.\x20Another\x20use\x20of\x20inhaled\x20NO\x20is\x20to\x20determine\x20the\x20<strong>diffusion\x20capacity\x20(DL)</strong>\x20across\x20the\x20alveolar-capillary\x20membrane.\x20It\x20is\x20more\x20effective\x20than\x20CO2\x20because\x20of\x20its\x20greater\x20affinity\x20for\x20hemoglobin\x20and\x20its\x20higher\x20water\x20solubility\x20at\x20body\x20temperature.</p>\x0a<p>NO\x20is\x20produced\x20from\x20the\x20nasal\x20passages\x20and\x20the\x20lungs\x20of\x20normal\x20human\x20subjects\x20and\x20can\x20be\x20detected\x20in\x20exhaled\x20gas.\x20The\x20measurement\x20of\x20fractional\x20<strong>exhaled\x20NO</strong>\x20is\x20a\x20<strong>noninvasive\x20marker</strong>\x20for\x20<strong>airway\x20inflammation</strong>\x20in\x20the\x20assessment\x20of\x20respiratory\x20tract\x20diseases,\x20including\x20<strong>asthma</strong>,\x20<strong>respiratory\x20tract\x20infection</strong>,\x20and\x20<strong>chronic\x20lung\x20disease</strong>.</p>\x0a<p>Inhaled\x20NO\x20is\x20administered\x20at\x20<strong>low\x20concentrations</strong>\x20(<strong>0.1–50\x20ppm</strong>)\x20since\x20high\x20concentrations\x20of\x2050\x20to\x20100\x20ppm\x20can\x20cause\x20significant\x20<strong>methemoglobinemia\x20</strong>that\x20can\x20cause\x20death.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Unstable\x20angina</strong>\x20is\x20treated\x20by\x20<strong>anti-platelet\x20drugs</strong>\x20such\x20as<strong>\x20</strong>aspirin\x20and\x20clopidogrel,\x20and\x20anticoagulants\x20such\x20as<strong>\x20heparin</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Obstructive\x20sleep\x20apnoea</strong>\x20is\x20mainly\x20treated\x20by\x20using\x20a\x20<strong>BiPAP\x20machine</strong>\x20during\x20sleep\x20and\x20<strong>CNS\x20stimulants</strong>\x20such\x20as\x20<strong>armodafinil</strong>\x20for\x20<strong>daytime\x20sleepiness</strong>\x20associated\x20with\x20the\x20condition.\u00a0</p>\x0a<p>Option\x20D:\x20<strong>Erectile\x20dysfunction</strong>\x20is\x20treated\x20by\x20<strong>PDE5\x20inhibitors</strong>\x20such\x20as\x20<strong>sildenafil</strong>,\x20tadalafil,\x20etc.</p>','1,3,4','lcHWV','accuracyScore','endsWith','search','EZnJf','lYbHA','a-ii,\x20b-iii,\x20c-i,\x20d-iv','pODML','Option\x20','solutionImages','445358XcvocF','click','VFyPJ','WhddZ','HqPZL','NXIMu','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','For\x20resistant\x20cases\x20of\x20malaria','Khmtp','FRBNA','<p>The\x20osmotic\x20diuretics\x20act\x20at\x20the\x20proximal\x20convoluted\x20tubule\x20and\x20the\x20potassium-sparing\x20diuretics\x20act\x20on\x20the\x20collecting\x20tubule.\x20Hence\x20C\x20and\x20D\x20are\x20the\x20right\x20statements.</p>\x0a<p>A\x20-\x20<strong>Osmotic\x20diuretics</strong>,\x20like\x20<strong>mannitol</strong>,\x20retain\x20water\x20isoosmotically\x20in\x20the\x20<strong>proximal\x20convoluted\x20tubule\x20</strong>(PCT)\x20and\x20descending\x20loop\x20of\x20Henle\x20which\x20are\x20freely\x20permeable\x20to\x20water.\x20Luminal\x20fluid\x20is\x20diluted\x20and\x20opposes\x20NaCl\x20reabsorption.\x20They\x20are\x20indicated\x20in\x20<strong>raised\x20intracranial</strong>\x20<strong>tension\x20</strong>and\x20in\x20<strong>dialysis\x20disequilibrium</strong>.</p>\x0a<p>B\x20-\x20<strong>Thiazides</strong>\x20act\x20on\x20the\x20<strong>distal\x20convoluted\x20tubule</strong>\x20(DCT).\x20They\x20block\x20the\x20<strong>Na+/Cl-\x20co-transporter</strong>\x20in\x20the\x20DCT.\x20This\x20results\x20in\x20the\x20loss\x20of\x20sodium,\x20chloride,\x20and\x20water\x20contributing\x20to\x20the\x20diuretic\x20effect.\x20Some\x20of\x20the\x20examples\x20are\x20hydrochlorothiazide,\x20chlorthalidone\x20and\x20metolazone.\x20Their\x20indications\x20include\x20<strong>hypertension</strong>,\x20edema,\x20<strong>diabetes\x20insipidus</strong>\x20and\x20<strong>hypercalciuria</strong>.</p>\x0a<p>C\x20-\x20<strong>Carbonic\x20anhydrase\x20inhibitors</strong>\x20act\x20on\x20the\x20<strong>proximal\x20convoluted\x20tubule</strong>\x20(PCT).\u00a0By\x20inhibiting\x20carbonic\x20anhydrase,\x20HCO3-\x20reabsorption\x20is\x20blocked\x20and\x20diuresis\x20occurs.\x20Examples\x20are\x20acetazolamide,\x20methazolamide,\x20dichlorphenamide,\x20and\x20dorzolamide.\x20They\x20are\x20used\x20in\x20the\x20treatment\x20of\x20<strong>glaucoma</strong>,\x20urinary\x20alkalinization\x20in\x20<strong>cystinuria</strong>,\x20management\x20of\x20<strong>metabolic\x20alkalosis</strong>,\x20and\x20<strong>acute\x20mountain\x20sickness</strong>.\u00a0</p>\x0a<p>D\x20-\x20<strong>Potassium-sparing\x20diuretics</strong>\x20include\x20<strong>aldosterone\x20antagonists\x20</strong>(spironolactone,\x20eplerenone)\x20and\x20<strong>inhibitors\x20of\x20renal\x20epithelial\x20Na+</strong>\x20<strong>channel\x20</strong>(triamterene,\x20amiloride).\x20They\x20act\x20on\x20the<strong>\x20late\x20distal\x20tubule</strong>\x20and\x20the\x20<strong>collecting\x20duct</strong>.\x20Aldosterone\x20antagonists\x20are\x20used\x20in\x20the\x20treatment\x20of\x20<strong>edema</strong>,\x20<strong>hypertension</strong>,\x20<strong>heart\x20failure</strong>\x20and\x20<strong>Conn\x27s\x20syndrome</strong>.\x20Amiloride\x20has\x20a\x20role\x20in<strong>\x20lithium-induced\x20diabetes\x20insipidus</strong>.</p>','Xucht','loadSource','<p>Therefore,\u00a0</p>\x0a<p>t1/2\x20~\x200.7\x20x\x2046x6/4.6\x20=\x200.7\x20x\x2060</p>\x0a<p>t1/2\x20~\x20<strong>42\x20hours</strong></p>\x0a<p>Where,</p>\x0a<p>t1/2\x20-\x20Plasma\x20half-life<br\x20/>Vd\x20-\x20Volume\x20of\x20distribution\u00a0<br\x20/>CL\x20-\x20Clearance\u00a0</p>','aJaRw','question_images','PYQs','AyuiA','voLHy','mBDfb','mPtws','Chlorpromazine','\x20>\x20','quizPerformanceData','QvQSE','console','XKDvA','TrHGt','Net\x20loss\x20of\x20bone\x20mass','68h','vqFMI','yorkH','RpRar','SykbM','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','UEnyf','YdAnb','yrOmO','lIMCE','findIndex','PwYJm','1,2','ABNID','Incorrect','The\x20drug\x20that\x20binds\x20to\x20CD4\x20and\x20has\x20action\x20on\x20both\x20CCR5\x20and\x20CXCR4\x20in\x20tropic\x20HIV\x20infections\x20is','eYejh','HcPon','WKmtI','length','lciQV','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','1,2,3','QpTBe','Lamotrigine','filter','1,2,4','2,\x204','PJJAU','sponM','studyModeLegend','bKoLj','Evolocumab','Qtlwh','ZpcKG','otjyX','mqtQz','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Persistent\x20pulmonary\x20hypertension\x20of\x20newborn','hcOHW','eNVEV','Obstructive\x20sleep\x20apnea','cinmX','sQHkF','BVHQP','customQuizData','EnRsL','xgJcW','igvOS','RkqQF','4765mkcuWu','fill','MYymW','vYljw','fLnnL','YhpmC','zgDth','FuViO','lweib','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','strokeDasharray','hGBcJ','ArZvE','stiiw','LMMBF','FJuDL','onclick','incorrect','cHDAX','isSupported','Bempedoic\x20acid','More\x20immunogenic\x20than\x20iron\x20dextran','appendChild','RpCwI','Choose\x20the\x20correct\x20option\x20regarding\x20phenytoin.','info','solutionContainer','Dapsone','totalTimeResult','Ganaxolone','UVWOK','lXEmf','glnqU','solutionVideo','zQkkQ','FEWBn','BDTFF','timed_exam','nav-btn-correct','vLSby','toLowerCase','pcvcD','<p>The\x20active\x20form\x20of\x20vitamin\x20D,\x20<strong>1,25-dihydroxyvitamin\x20D\x20(calcitriol)</strong>,\x20directly<strong>\x20suppresses\x20PTH\x20gene\x20expression</strong></p>\x0a<p><strong>Calcitriol</strong>\x20is\x20the\x20active\x20form\x20of\x20<strong>vitamin</strong>\x20<strong>D</strong>.\x20It\x20increases\x20<strong>calcium\x20absorption</strong>\x20from\x20the\x20<strong>intestines</strong>\x20and\x20helps\x20maintain\x20<strong>adequate\x20serum\x20calcium\x20levels.</strong>\x20When\x20calcium\x20levels\x20rise,\x20this\x20triggers\x20a\x20<strong>negative\x20feedback\x20mechanism</strong>\x20on\x20the\x20parathyroid\x20glands,\x20leading\x20to\x20<strong>decreased\x20secretion</strong>\x20of\x20<strong>parathyroid\x20hormone</strong>\x20(PTH).\x20PTH\x27s\x20primary\x20role\x20is\x20to\x20raise\x20<strong>blood\x20calcium</strong>\x20levels,\x20so\x20when\x20<strong>calcium</strong>\x20is\x20<strong>sufficient,</strong>\x20the\x20need\x20for\x20<strong>PTH\x20decreases,</strong>\x20resulting\x20in\x20<strong>lower\x20PTH</strong>\x20levels.</p>\x0a<p><strong>Vitamin</strong>\x20D\x20and\x20its\x20derivatives\x20are\x20the\x20primary\x20treatment\x20for\x20<strong>hypoparathyroidism.\x20Dihydrotachysterol</strong>\x20(DHT),\x20a\x20reduced\x20form\x20of\x20vitamin\x20D2,\x20has\x20a\x20<strong>quicker\x20onset,\x20shorter\x20duration,</strong>\x20and\x20<strong>stronger\x20impact</strong>\x20on\x20<strong>bone\x20mobilization</strong>\x20than\x20traditional\x20vitamin\x20D,\x20making\x20it\x20a\x20preferred\x20option.\x20While\x20most\x20<strong>hypoparathyroid\x20patients</strong>\x20respond\x20well\x20to\x20any\x20form\x20of\x20<strong>vitamin</strong>\x20<strong>D</strong>,\x20calcitriol\x20may\x20be\x20preferred\x20for\x20<strong>temporary\x20treatment</strong>\x20of\x20<strong>hypocalcemia</strong>\x20while\x20waiting\x20for\x20the\x20effects\x20of\x20a\x20<strong>slower-acting\x20vitamin</strong>\x20<strong>D</strong>\x20form.\x20Calcium\x20is\x20used\x20to\x20address\x20<strong>calcium\x20deficiency</strong>\x20and\x20as\x20a\x20<strong>dietary\x20supplement.\x20Vitamin</strong>\x20<strong>D</strong>\x20is\x20the\x20<strong>primary\x20treatment</strong>\x20for\x20<strong>hypoparathyroidism.</strong></p>\x0a<p><strong>Severe\x20hypermagnesemia</strong>\x20or\x20<strong>hypomagnesemia</strong>\x20can\x20also\x20inhibit\x20PTH\x20secretion.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B:\x20<strong>Risedronate</strong>\x20is\x20a\x20<strong>bisphosphonate</strong>\x20that\x20<strong>inhibits\x20bone\x20resorption,</strong>\x20but\x20it\x20doesn\x27t\x20directly\x20affect\x20PTH\x20secretion.</p>\x0a<p>Option\x20C:\x20<strong>Furosemide</strong>\x20is\x20a\x20<strong>diuretic</strong>\x20that\x20can\x20<strong>increase\x20calcium\x20excretion,</strong>\x20potentially\x20raising\x20PTH\x20as\x20the\x20body\x20tries\x20to\x20conserve\x20calcium.</p>\x0a<p>Option\x20D:\x20<strong>Lithium</strong>\x20can\x20actually\x20<strong>increase\x20PTH\x20secretion</strong>\x20by\x20affecting\x20<strong>calcium-sensing</strong>\x20receptors\x20in\x20the\x20parathyroid\x20glands.</p>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','map','Hydrochlorothiazide','CrpfI','closest','<p><strong>1,2\x20and\x204</strong>\x20can\x20be\x20added\x20based\x20on\x20his\x20lipid\x20profile.</p>\x0a<p>A\x20patient\x20with\x20hypertension\x20and\x20diabetes\x20who\x20underwent\x20PCI\x20stent\x20placement\x20for\x20NSTEMI\x20has\x20<strong>atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)</strong>.\x20The\x20treatment\x20goal\x20in\x20patients\x20with\x20ASCVD\x20is\x20to\x20<strong>decrease\x20LDL\x20levels</strong>.</p>\x0a<p>Ezetemibe,\x20Evolocumab,\x20Bemepedoic\x20acid\x20decrease\x20LDL.\x20<strong>Gemfibrozil</strong>\x20mainly\x20decreases\x20<strong>triglycerides</strong>\x20and\x20not\x20LDL.</p>\x0a<p>1.\x20<strong>Evolocumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20inhibits\x20PCSK-9\x20(proprotein\x20convertase\x20subtilisin/kexin).\x20Inhibition\x20of\x20PCSK-9\x20prevents\x20the\x20degradation\x20of\x20LDL\x20receptors\x20and\x20thus\x20increases\x20LDL-cholesterol\x20clearance\x20by\x20the\x20liver.\x20They\x20are\x20used\x20in\x20patients\x20with\x20atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)\x20to\x20decrease\x20LDL\x20levels.</p>\x0a<p>2.\x20<strong>Ezetimibe</strong>\x20inhibits\x20cholesterol\x20absorption\x20by\x20enterocytes\x20in\x20the\x20small\x20intestine.\x20It\x20lowers\x20the\x20total\x20and\x20LDL-C\x20levels.</p>\x0a<p>3.\x20<strong>Gemfibrozil\x20</strong>belongs\x20to\x20the\x20fibrate\x20group\x20of\x20drugs\x20that\x20binds\x20to\x20peroxisome\x20proliferator-activated\x20receptors\x20(PPARα),\x20which\x20stimulate\x20fatty\x20acid\x20oxidation\x20and\x20thereby\x20reduce\x20triglyceride\x20levels\x20mainly.</p>\x0a<p>4.\x20<strong>Bempedoic\x20acid</strong>\x20inhibits\x20adenosine\x20triphosphate-citrate\x20lyase\x20(ACL)\x20and\x20results\x20in\x20decreased\x20LDL\x20in\x20patients\x20not\x20responding\x20to\x20statin\x20therapy.</p>\x0a<p>Note\x20-\x20Ezetimibe,\x20colestipol,\x20bempedoic\x20acid\x20and\x20PCSK-9\x20inhibitors\x20like\x20alirocumab\x20have\x20been\x20proven\x20to\x20reduce\x20atherosclerosis\x20risk\x20when\x20added\x20to\x20statins,\x20whereas\x20the\x20fibrate\x20group\x20of\x20drugs\x20and\x20niacin\x20show\x20no\x20significant\x20effect\x20in\x20addition\x20to\x20statins.</p>','pathname','vlARj','bHUgM','LHSTB','uoIyU','Lithium','GbaHd','Only\x201\x20and\x202','PGcOs','border-red-500','join','key','fAddh','xFPMe','ethUe','yGkzY','UujYe','dDeKP','xkHPw','TneIZ','startAt','timeSpent','totalTime','keydown','AriqO','scoreCircle','UXjee','Codeine\x20as\x20it\x20is\x20a\x20potent\x20drug\x20and\x20quickly\x20relieves\x20symptoms.','INCYw','Dextromethorphan\x20alone\x20as\x20it\x20does\x20not\x20have\x20addictive\x20potential\x20like\x20codeine','dwniO','nBFVp','mgBFV','qFlHw','ZkdWu','Correct','evXWV','testModeLegend','ALuKi','iGTUi','GQZkM','eGVDc','itWQW','Glimepiride','timed_study','KUZpD','uOqIk','Marked','xNkcA','round','dxyOm','Mark\x20for\x20Review','title','notAttemptedResult','https://cdn1.dailyrounds.org/uploads/921730699eae46c3843301d7d92a1f02.JPEG','quizSidebar','Maraviroc','STjmD','hzsyp','Marrow','BpURx','Enoxaparin','JEosk','AahjM','<p><strong>Rucaparib</strong>\x20is\x20an\x20inhibitor\x20of\x20<strong>Poly\x20ADP\x20ribose\x20polymerase\x20(PARP)</strong>\x20used\x20for\x20<strong>BRCA-positive\x20breast\x20cancers</strong>.\u00a0</p>\x0a<p>Rucaparib\x20is\x20a\x20poly\x20ADP-ribose\x20polymerase/\x20PARP\x20inhibitor\x20approved\x20for\x20the\x20treatment\x20of\x20breast\x20and\x20advanced\x20ovarian\x20cancer.</p>\x0a<p>PARP\x20is\x20a\x20nuclear\x20protein\x20that\x20transfers\x20ADP-ribose\x20from\x20NAD+\x20to\x20target\x20proteins\x20and\x20this\x20plays\x20an\x20important\x20role\x20in\x20the\x20DNA\x20damage\x20response.\x20Rucaparib\x20and\x20olaparib\x20are\x20PARP\x20inhibitors.</p>\x0a<p>Inhibitors\x20of\x20<strong>PARP\x20(Poly\x20ADP\x20Ribosyl\x20Polymerase)</strong>\x20approved\x20for\x20breast\x20cancer:</p>\x0a<ul>\x0a<li>Olaparib</li>\x0a<li>Rucaparib</li>\x0a<li>Talazoparib</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Palbociclib</strong>\x20is\x20a\x20selective\x20inhibitor\x20of\x20the\x20cyclin-dependent\x20kinases\x20CDK4\x20and\x20CDK6.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20metastatic\x20breast\x20cancer.\u00a0</p>\x0a<p>Option\x20C:\x20<strong>Regorafenib</strong>\x20is\x20an\x20angiogenesis\x20inhibitor\x20that\x20is\x20indicated\x20as\x20a\x20second-line\x20treatment\x20for\x20unresectable\x20hepatocellular\x20carcinoma.\x20(The\x20first\x20line\x20is\x20Sorafenib).</p>\x0a<p>Option\x20D:\x20<strong>Vandetanib</strong>\x20is\x20an\x20oral\x20tyrosine\x20kinase\x20inhibitor\x20recently\x20FDA-approved\x20for\x20unresectable\x20locally\x20advanced\x20or\x20metastatic\x20medullary\x20thyroid\x20carcinoma.</p>','lEBrf','Which\x20of\x20the\x20following\x20drugs\x20acts\x20as\x20an\x20inhibitor\x20of\x20PCSK-9?','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','timeDisplay','fMnLc','sHxmb','includes','TNJpB','Cetuximab','RnqBq','XfXkU','reduce','JYcrg','div','mUOFD','Finerenone','zSYsw','ygXBp','Lepirudin','1,\x202\x20and\x204','HsYio','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','10WRZsRZ','mQfjo','gKpAf','dEoJb','UfCdt','Angiotensin\x20receptor\x20blockers','1,3\x20and\x204','RAcwY','CKzpo','FHdgO','oCFTC'];_0x421b=function(){return _0x4862ce;};return _0x421b();}function toggleBookmark(){const _0x23e06f=_0x3c9c61,_0x15e25b={'oKPQq':_0x23e06f(0x423),'CTJOa':function(_0x200c76){return _0x200c76();},'gZshG':function(_0x8706c2){return _0x8706c2();}},_0x3a1c50=!questionStates[currentQuestionIndex][_0x23e06f(0x3f9)];questionStates[currentQuestionIndex][_0x23e06f(0x3f9)]=_0x3a1c50;let _0x41f2d6=JSON[_0x23e06f(0x3ef)](localStorage[_0x23e06f(0x39b)](_0x23e06f(0x423)))||[];if(_0x3a1c50){const _0x13cb08={'quizName':quizName,'quizFile':window[_0x23e06f(0x407)][_0x23e06f(0x280)][_0x23e06f(0x3fa)]('/')[_0x23e06f(0x367)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x23e06f(0x43b)]()};_0x41f2d6[_0x23e06f(0x404)](_0x13cb08);}else _0x41f2d6=_0x41f2d6[_0x23e06f(0x235)](_0xe90419=>!(_0xe90419['quizFile'][_0x23e06f(0x2c7)](quizName['toLowerCase']()[_0x23e06f(0x357)](/ /g,'-'))&&_0xe90419['questionIndex']===currentQuestionIndex));localStorage[_0x23e06f(0x1e4)](_0x15e25b[_0x23e06f(0x467)],JSON[_0x23e06f(0x2f2)](_0x41f2d6)),_0x15e25b[_0x23e06f(0x48d)](updateBookmarkButton),_0x15e25b['gZshG'](updateQuestionNav);}function updateBookmarkButton(){const _0x33b20e=_0x3c9c61,_0x3a16da={'ldnXp':_0x33b20e(0x3fe),'FRBNA':_0x33b20e(0x3e9),'XKDvA':_0x33b20e(0x242),'mmBbl':_0x33b20e(0x4a2),'lNmbq':_0x33b20e(0x33c)},_0xbf1187=document[_0x33b20e(0x3e4)](_0x33b20e(0x45a)),_0x19cff6=document[_0x33b20e(0x3e4)](_0x3a16da['ldnXp']),_0x50e93a=questionStates[currentQuestionIndex][_0x33b20e(0x3f9)];_0xbf1187[_0x33b20e(0x400)]=_0x50e93a?_0x3a16da[_0x33b20e(0x208)]:_0x3a16da[_0x33b20e(0x219)],_0x19cff6['textContent']=_0x50e93a?_0x3a16da[_0x33b20e(0x354)]:_0x3a16da[_0x33b20e(0x3d2)];}function toggleMarkForReview(){const _0x3085f2=_0x3c9c61,_0x634268={'lTTxU':function(_0x20e93e){return _0x20e93e();},'jnYtq':function(_0x35ea82){return _0x35ea82();}};questionStates[currentQuestionIndex][_0x3085f2(0x385)]=!questionStates[currentQuestionIndex][_0x3085f2(0x385)],_0x634268[_0x3085f2(0x46a)](updateMarkReviewButton),_0x634268['jnYtq'](updateQuestionNav);}function updateMarkReviewButton(){const _0x395547=_0x3c9c61,_0x3222f2={'UpDXM':_0x395547(0x3c6),'ftthz':_0x395547(0x493),'adNcp':_0x395547(0x477),'XSNcO':_0x395547(0x2af),'stiiw':_0x395547(0x2b3)},_0x1c5981=document[_0x395547(0x3e4)](_0x3222f2[_0x395547(0x381)]),_0x986414=document['getElementById'](_0x3222f2['ftthz']),_0x10b1b4=questionStates[currentQuestionIndex][_0x395547(0x385)];_0x1c5981[_0x395547(0x400)]=_0x10b1b4?'gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center':_0x3222f2['adNcp'],_0x986414['textContent']=_0x10b1b4?_0x3222f2[_0x395547(0x390)]:_0x3222f2[_0x395547(0x25c)];}function previousQuestion(){const _0x4e085f=_0x3c9c61,_0x4d11e6={'ZGRWo':function(_0x37c4c1){return _0x37c4c1();},'KvYsy':function(_0x3f46da,_0x1f3878){return _0x3f46da>_0x1f3878;},'zSYsw':function(_0x350740,_0x1f80ba){return _0x350740===_0x1f80ba;},'jPeMI':_0x4e085f(0x2aa),'cHDAX':function(_0x19e9ff,_0xfd5286){return _0x19e9ff-_0xfd5286;}};_0x4d11e6['KvYsy'](currentQuestionIndex,0x0)&&(_0x4d11e6[_0x4e085f(0x2d1)](_0x4d11e6[_0x4e085f(0x1f0)],_0x4d11e6[_0x4e085f(0x1f0)])?(questionStartTime&&(questionStates[currentQuestionIndex][_0x4e085f(0x295)]+=_0x4d11e6[_0x4e085f(0x261)](Date[_0x4e085f(0x43b)](),questionStartTime)),currentQuestionIndex--,displayQuestion()):_0x4d11e6[_0x4e085f(0x34a)](_0xd5d9d8));}function _0x47ec(_0x211c83,_0x4a68e5){const _0x139747=_0x421b();return _0x47ec=function(_0x110796,_0x5b51cf){_0x110796=_0x110796-0x1e4;let _0xf30a42=_0x139747[_0x110796];return _0xf30a42;},_0x47ec(_0x211c83,_0x4a68e5);}function nextQuestion(){const _0x51743f=_0x3c9c61,_0x9140a4={'HRYyo':function(_0x1a32b4,_0x3126bc){return _0x1a32b4-_0x3126bc;},'vWUjP':function(_0x147b6a){return _0x147b6a();},'RnqBq':'.m3u8','VFyPJ':function(_0x4f9aee,_0x3fd260){return _0x4f9aee!==_0x3fd260;},'QuKgR':_0x51743f(0x38e),'laITC':_0x51743f(0x459),'VtwuF':function(_0x397315,_0x1d05c1){return _0x397315-_0x1d05c1;},'KyQKH':function(_0x2ef8e0,_0x2ecfe5){return _0x2ef8e0<_0x2ecfe5;},'ZMppK':function(_0x51596c,_0x1df6b1){return _0x51596c-_0x1df6b1;},'uZPhY':function(_0xd57edb,_0x5b88bd){return _0xd57edb===_0x5b88bd;},'JAlKt':_0x51743f(0x2f7),'aWenT':'kAqoG','NaRkD':_0x51743f(0x306),'ZkdWu':'timed_exam','FHdgO':function(_0x27208a,_0x57a158){return _0x27208a(_0x57a158);},'aaxrK':function(_0x4757a7,_0x359c8d){return _0x4757a7!==_0x359c8d;},'JNMnU':'LLdEq','iWmQo':function(_0x47dbfb){return _0x47dbfb();},'OIGyC':function(_0x25c61c,_0x1c2b41){return _0x25c61c(_0x1c2b41);}};questionStartTime&&(_0x9140a4[_0x51743f(0x201)](_0x9140a4[_0x51743f(0x418)],_0x9140a4[_0x51743f(0x447)])?questionStates[currentQuestionIndex][_0x51743f(0x295)]+=_0x9140a4['VtwuF'](Date['now'](),questionStartTime):(_0x8b3047&&(_0x1bd635[_0x4ce2e1][_0x51743f(0x295)]+=_0x9140a4['HRYyo'](_0x1251a5['now'](),_0x53e75d)),_0x4caa04=_0x12f3e4,_0x9140a4[_0x51743f(0x3f4)](_0x5c4625)));if(_0x9140a4['KyQKH'](currentQuestionIndex,_0x9140a4[_0x51743f(0x44a)](questionsData['length'],0x1)))currentQuestionIndex++,_0x9140a4[_0x51743f(0x3f4)](displayQuestion);else{if(_0x9140a4[_0x51743f(0x4ab)](_0x9140a4['JAlKt'],_0x9140a4['aWenT'])){const _0x124e85=_0x2f2921[_0x51743f(0x3cd)][_0x51743f(0x434)];if(_0x124e85&&_0x124e85[_0x51743f(0x2c7)](_0x9140a4[_0x51743f(0x2ca)]))_0x29922b(_0x2312c0,_0x124e85);else _0x124e85&&(_0x44b26a[_0x51743f(0x434)]=_0x124e85);}else{if(_0x9140a4[_0x51743f(0x4ab)](currentMode,_0x9140a4[_0x51743f(0x476)])||currentMode===_0x9140a4[_0x51743f(0x2a2)]){if(_0x9140a4[_0x51743f(0x2e0)](confirm,'You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?')){if(_0x9140a4[_0x51743f(0x373)](_0x9140a4[_0x51743f(0x3f8)],_0x9140a4[_0x51743f(0x3f8)])){_0x33b1af[_0x51743f(0x40c)]++,_0x42bc41[_0x51743f(0x478)]--;if(_0x3509b6)_0x34c91f[_0x51743f(0x44b)]++;else _0x28dcbd[_0x51743f(0x46e)]++;}else _0x9140a4['iWmQo'](submitQuiz);}}else _0x9140a4[_0x51743f(0x349)](confirm,_0x51743f(0x392))&&(currentQuestionIndex=0x0,_0x9140a4[_0x51743f(0x3f4)](displayQuestion));}}}function startTimer(){const _0x5914a1=_0x3c9c61,_0x21e54c={'FFtgM':'questionNav','fAddh':function(_0x5b4e05,_0x118570){return _0x5b4e05<_0x118570;},'RpCwI':function(_0xe722e1,_0x4947e6){return _0xe722e1+_0x4947e6;},'iAVga':'w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','sjANR':function(_0x254eae){return _0x254eae();},'AeouO':function(_0x303771,_0x3959d8){return _0x303771(_0x3959d8);},'YnUSe':_0x5914a1(0x392),'aJaRw':function(_0x1ea738,_0x2a79f4){return _0x1ea738!==_0x2a79f4;},'STjmD':_0x5914a1(0x47e),'oCFTC':function(_0x3f26d4,_0x23916b){return _0x3f26d4===_0x23916b;},'ULduI':_0x5914a1(0x257),'xuaBB':function(_0x57b310,_0x2a0e50){return _0x57b310===_0x2a0e50;},'WKmtI':'timed_exam','bHUgM':'WIsAr','WirUb':'dmZQY','SGTsm':function(_0x5768f3,_0x22f649,_0xc2a19c){return _0x5768f3(_0x22f649,_0xc2a19c);}};if(timer)clearInterval(timer);timeRemaining=0x78,updateTimerDisplay(),timer=_0x21e54c['SGTsm'](setInterval,()=>{const _0x2b1e75=_0x5914a1,_0x3b9803={'OVMeU':function(_0x310d46,_0x537c31){const _0x310dd7=_0x47ec;return _0x21e54c[_0x310dd7(0x1e8)](_0x310d46,_0x537c31);},'SjOoo':_0x21e54c[_0x2b1e75(0x3a0)],'rblfX':function(_0x781e9c){return _0x21e54c['sjANR'](_0x781e9c);}};if(_0x21e54c[_0x2b1e75(0x20d)](_0x21e54c[_0x2b1e75(0x2b9)],_0x21e54c[_0x2b1e75(0x2b9)])){const _0x3d7ff0=_0x52e707['getElementById'](_0x21e54c['FFtgM']);_0x3d7ff0[_0x2b1e75(0x49f)]='';for(let _0x51b5e0=0x0;_0x21e54c[_0x2b1e75(0x28c)](_0x51b5e0,_0x138564['length']);_0x51b5e0++){const _0x56b572=_0x14d7b6[_0x2b1e75(0x379)](_0x2b1e75(0x488));_0x56b572[_0x2b1e75(0x411)]=_0x21e54c[_0x2b1e75(0x266)](_0x51b5e0,0x1),_0x56b572[_0x2b1e75(0x400)]=_0x21e54c['iAVga'],_0x56b572['onclick']=()=>_0x4be07d(_0x51b5e0),_0x56b572['id']=_0x2b1e75(0x364)+_0x51b5e0,_0x3d7ff0['appendChild'](_0x56b572);}_0x21e54c['sjANR'](_0x95308);}else{timeRemaining--,_0x21e54c[_0x2b1e75(0x408)](updateTimerDisplay);if(timeRemaining<=0x0){if(_0x21e54c[_0x2b1e75(0x2e1)](_0x21e54c['ULduI'],_0x2b1e75(0x257)))_0x21e54c[_0x2b1e75(0x1e8)](clearInterval,timer),_0x21e54c[_0x2b1e75(0x494)](currentMode,_0x21e54c[_0x2b1e75(0x22e)])?_0x21e54c[_0x2b1e75(0x2e1)](_0x21e54c[_0x2b1e75(0x282)],_0x21e54c[_0x2b1e75(0x346)])?_0x3b9803['OVMeU'](_0x53bdbc,_0x3b9803[_0x2b1e75(0x312)])&&(_0x174f53=0x0,_0x3b9803[_0x2b1e75(0x472)](_0x3bbb3f)):_0x21e54c[_0x2b1e75(0x408)](submitQuiz):_0x21e54c[_0x2b1e75(0x408)](nextQuestion);else{const _0x247ad7=_0x232297['apply'](_0x1ea840,arguments);return _0x1ca2f3=null,_0x247ad7;}}}},0x3e8);}function updateTimerDisplay(){const _0xc8f038=_0x3c9c61,_0x87465={'QlszE':function(_0x18e907,_0x8901a7){return _0x18e907/_0x8901a7;},'ERfrN':function(_0x212bd0,_0x4be8ac){return _0x212bd0%_0x4be8ac;},'uDhbb':_0xc8f038(0x2c4),'HiLio':function(_0x5bd898,_0x53353b){return _0x5bd898+_0x53353b;}},_0x238ebc=Math[_0xc8f038(0x45e)](_0x87465['QlszE'](timeRemaining,0x3c)),_0x335fe5=_0x87465[_0xc8f038(0x324)](timeRemaining,0x3c);document[_0xc8f038(0x3e4)](_0x87465[_0xc8f038(0x47a)])[_0xc8f038(0x411)]=_0x87465[_0xc8f038(0x2f4)](_0x238ebc,':')+_0x335fe5[_0xc8f038(0x39d)]()[_0xc8f038(0x3a7)](0x2,'0');}function toggleSidebar(){const _0x32b221=_0x3c9c61,_0x26e8e4={'XWOZV':_0x32b221(0x2b7),'USUBW':_0x32b221(0x337)};document[_0x32b221(0x3e4)](_0x26e8e4[_0x32b221(0x313)])['classList'][_0x32b221(0x3c0)](_0x26e8e4[_0x32b221(0x471)]);}document[_0x3c9c61(0x435)](_0x3c9c61(0x2e6),()=>{const _0xac014f=_0x3c9c61,_0x27096a={'iLxgA':function(_0x13caf1,_0x17aa4f){return _0x13caf1(_0x17aa4f);},'pZCsD':_0xac014f(0x4a4),'FuViO':_0xac014f(0x375),'bNkmP':_0xac014f(0x24a),'lIMCE':_0xac014f(0x448),'ooxcy':function(_0x15dbcd,_0x408283){return _0x15dbcd===_0x408283;},'Kvnpb':'NDFRT','sQHkF':_0xac014f(0x327),'QJMir':function(_0x36979f){return _0x36979f();}};!window[_0xac014f(0x407)][_0xac014f(0x280)][_0xac014f(0x1f7)](_0x27096a[_0xac014f(0x256)])?document[_0xac014f(0x3e4)](_0xac014f(0x431))[_0xac014f(0x344)][_0xac014f(0x40d)]=_0x27096a[_0xac014f(0x225)]:_0x27096a['ooxcy'](_0x27096a[_0xac014f(0x495)],_0x27096a[_0xac014f(0x248)])?_0x27096a['iLxgA'](_0x5f1b48,_0x27096a[_0xac014f(0x319)])&&(_0x428000[_0xac014f(0x407)][_0xac014f(0x280)][_0xac014f(0x1f7)](_0x27096a[_0xac014f(0x256)])&&_0x2d2ed3[_0xac014f(0x35f)](_0x27096a[_0xac014f(0x429)]),_0xb54f89[_0xac014f(0x3b1)]()):_0x27096a[_0xac014f(0x38d)](initializeQuiz);}),document[_0x3c9c61(0x435)](_0x3c9c61(0x297),function(_0x440cbf){const _0x39becd=_0x3c9c61,_0x114fec={'Xucht':function(_0x29bacc){return _0x29bacc();},'XZeGg':_0x39becd(0x3c6),'Fgrrc':_0x39becd(0x493),'RoLem':_0x39becd(0x2af),'TIeZf':_0x39becd(0x2b3),'AriqO':_0x39becd(0x431),'fLnnL':function(_0x1a7309,_0x4911a7){return _0x1a7309===_0x4911a7;},'ERabR':function(_0x5635f7,_0x25e61a){return _0x5635f7-_0x25e61a;},'JjGwf':_0x39becd(0x440),'sHxmb':function(_0x2d50b1,_0x499962){return _0x2d50b1<_0x499962;},'hfILz':function(_0x89472d,_0x49666a){return _0x89472d(_0x49666a);},'cEjqc':function(_0xf5d36,_0x240b0f){return _0xf5d36===_0x240b0f;},'LROXG':function(_0xcbe305,_0x2d8b11){return _0xcbe305===_0x2d8b11;},'VPMDS':_0x39becd(0x34b),'TPDio':_0x39becd(0x24d),'chlQd':_0x39becd(0x4a5),'TtLVt':function(_0xd6c58e,_0x3b7c5e){return _0xd6c58e===_0x3b7c5e;},'TWBgT':_0x39becd(0x2ac),'KwNhQ':_0x39becd(0x286),'DSnST':_0x39becd(0x31b),'bKMvQ':'test','SykbM':_0x39becd(0x274),'YoMXZ':function(_0x4634cb,_0x37881c){return _0x4634cb!==_0x37881c;},'ZVmdm':'EPxab','yorkH':_0x39becd(0x1e7),'MwxUF':function(_0xc61d4c){return _0xc61d4c();},'dwniO':function(_0x23e5d5,_0x34157a){return _0x23e5d5===_0x34157a;}};if(document['getElementById'](_0x114fec[_0x39becd(0x298)])[_0x39becd(0x344)][_0x39becd(0x40d)]!==_0x39becd(0x2e9))return;if(_0x114fec[_0x39becd(0x253)](document[_0x39becd(0x3e4)](_0x39becd(0x342))[_0x39becd(0x3c9)]['contains'](_0x39becd(0x3f1)),![]))return;if(_0x440cbf[_0x39becd(0x28b)]>='1'&&_0x440cbf[_0x39becd(0x28b)]<='4'){const _0x47e3dc=_0x114fec[_0x39becd(0x492)](parseInt(_0x440cbf[_0x39becd(0x28b)]),0x1),_0x5bfde0=document[_0x39becd(0x32e)](_0x114fec[_0x39becd(0x1eb)]);if(_0x114fec[_0x39becd(0x2c6)](_0x47e3dc,_0x5bfde0['length']))_0x114fec[_0x39becd(0x443)](selectOption,_0x47e3dc);}else{if(_0x114fec[_0x39becd(0x334)](_0x440cbf[_0x39becd(0x28b)],'ArrowLeft'))_0x114fec['Xucht'](previousQuestion);else{if(_0x114fec['LROXG'](_0x440cbf[_0x39becd(0x28b)],_0x114fec[_0x39becd(0x322)])||_0x114fec['fLnnL'](_0x440cbf['key'],'\x20'))_0x114fec['TPDio']!==_0x39becd(0x24d)?_0x114fec['Xucht'](_0x517027):(_0x440cbf['preventDefault'](),_0x114fec[_0x39becd(0x20a)](nextQuestion));else{if(_0x114fec['cEjqc'](_0x440cbf[_0x39becd(0x28b)][_0x39becd(0x277)](),'b')&&(currentMode===_0x114fec['chlQd']||_0x114fec[_0x39becd(0x328)](currentMode,_0x114fec[_0x39becd(0x335)]))){if(_0x114fec[_0x39becd(0x3ed)](_0x114fec['KwNhQ'],_0x114fec[_0x39becd(0x32c)])){const _0x3a9ef7=_0x2856e1[_0x39becd(0x3e4)](_0x114fec[_0x39becd(0x49b)]),_0x54d0f7=_0x511b10[_0x39becd(0x3e4)](_0x114fec[_0x39becd(0x38a)]),_0x5a9a30=_0x4dd1b8[_0x1f13fa]['markedForReview'];_0x3a9ef7[_0x39becd(0x400)]=_0x5a9a30?_0x39becd(0x350):_0x39becd(0x477),_0x54d0f7['textContent']=_0x5a9a30?_0x114fec[_0x39becd(0x36d)]:_0x114fec[_0x39becd(0x420)];}else toggleBookmark();}else{if(_0x114fec[_0x39becd(0x3ed)](_0x440cbf[_0x39becd(0x28b)][_0x39becd(0x277)](),'m')&&(currentMode===_0x114fec['bKMvQ']||currentMode===_0x114fec[_0x39becd(0x220)])){if(_0x114fec[_0x39becd(0x450)](_0x114fec[_0x39becd(0x2e7)],_0x114fec[_0x39becd(0x21e)]))_0x114fec['MwxUF'](toggleMarkForReview);else{const _0x321b82={'quizName':_0x46047d,'quizFile':_0x3279a5['location']['pathname']['split']('/')['pop'](),'questionIndex':_0x58ce34,'question':_0x5cb470[_0x14976e],'hierarchy':_0x46e66c,'timestamp':_0x24ebc3[_0x39becd(0x43b)]()};_0xb65f0a['push'](_0x321b82);}}else _0x440cbf['key'][_0x39becd(0x277)]()==='s'&&(_0x114fec[_0x39becd(0x29e)](currentMode,_0x114fec['bKMvQ'])||currentMode===_0x114fec[_0x39becd(0x220)])&&_0x114fec[_0x39becd(0x20a)](submitQuiz);}}}}});</script>

</body></html>